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ABSTRACT 
Type I hexokinase (HKI) is the pacemaker of glycolysis in the brain and red blood 
cell.  Recent work has tied hexokinase association with the mitochondrial membrane to the 
prevention of apoptosis.  With increased hexokinase activity and expression in tumor cells, 
the importance in understanding the release of HKI from the membrane has become 
extremely important.  Glucose 6-phosphate and nucleotides have been shown to effectively 
release HKI from the membrane; however, the mechanisms by which these molecules can 
induce release have never been studied.   
Expressed recombinant HKI protein was lacking the N-terminus that is required for 
binding to the mitochondrial membrane.  A new construct with a ten histidine tail at the C-
terminus was created and found to have an intact N-terminus.  Glucose 6-phosphate, a 
product and potent inhibitor of HKI, has been shown to bind to two different sites on the 
protein, but the inhibitor binds to only one site under physiological conditions in solution 
kinetic experiments.  A series of site-directed mutations aimed at removing the ability of HKI 
to bind glucose 6-phosphate were made.  After analysis, it has been determined that the N-
terminal half glucose 6-phosphate binding site of HKI is responsible for releasing HKI from 
the mitochondria 
Chapter III addresses the topic of ATP-induced release of HKI from the 
mitochondrial membrane.  X-ray crystallography revealed a nucleotide binding site near the 
N-terminal binding helix of hexokinase I. A similar set of mutations found in Chapter II 
along with mutations in the nucleotide binding site, were used to identify the site responsible 
for nucleotide-induced release from the mitochondria.  However, it was determined that ATP 
appears to be binding to porin or the mitochondrial membrane and not HKI. 
 vi 
   
 Chapter IV contains a series of solution kinetic experiments were conducted to assign 
a role to the N-terminal nucleotide binding site.  Forty years ago, ADP was shown to be a 
noncompetitive inhibitor relative to ATP.  The allosteric site responsible for causing the 
mixed inhibition was never identified.  Using site-directed mutations of HKI illustrated in 
Chapter III, the nucleotide site near the N-terminus was indeed found to be the allosteric 
nucleotide binding site.  
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CHAPTER I.  INTRODUCTION 
 
Hexokinase (ATP:D-hexose 6-phospho-transferase (2.7.1.1)) catalyzes the reaction of  
glucose and ATP to form glucose 6-phosphate (Glu-6-P) and ADP (1-3).  As one of four 
isozymes of hexokinase in mammals, Type I hexokinase (HKI) is the predominant form of 
hexokinase in brain tissue (1-3) and has been named the “pacemaker of glycolysis” (4).  
Increased hexokinase activity has been reported in tumor cells (5,6), and recent experiments 
have found that HKI can block the signal to begin apoptosis: the release of cytochrome c 
from the mitochondria (7). 
Hexokinases I-III are 100 kD proteins that are considered to have been formed 
through gene duplication and fusion of an ancestral 50 kD hexokinase gene similar to the 
types of hexokinases found in bacteria (8).   The different isozymes differ in tissue 
distribution, subcellular location and kinetic behavior (9).  While Type I is expressed in 
nearly all tissues, it is the predominant form found in the red blood cell and brain tissue.  
Type II is found in muscle and adipose tissues, while Type III is found predominantly in 
kidney, and Type IV protein is found in liver (9).  The Type I and II proteins have been 
shown to be attached to the mitochondrial membrane (9,10).  Hexokinase III is associated 
with the nuclear periphery (11).  In terms of kinetic behaviors, Types I-III are inhibited by 
the reaction product, Glu-6-P, while Type IV is unaffected (9). 
Through evolution the two halves of hexokinase I have diverged in their functions 
(8).  The C-terminal half contains the active site of the protein, while the N-terminal half of 
HKI has no catalytic activity but has been shown to have regulatory properties (12).  The 
product of the hexokinase reaction, Glu-6-P, is a competitive inhibitor with respect to ATP 
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and a linear noncompetitive inhibitor with respect to glucose (13).  Physiological 
concentrations of inorganic phosphate can relieve this inhibition (10).The structure of HKI 
(Fig. 1.1) has been solved by X-ray crystallography (14-18).  HKI is composed of two 
structurally similar globes separated by a connecting helix.  Glucose 6-phosphate was found 
to bind to both halves in crystallographic conditions.  While the N-terminal half of the 
protein is catalytically inactive, it does contain a nearly equivalent binding pocket for glucose 
and Glu-6-P.  In addition, the N-terminal half contains the mitochondrial binding helix 
located at the N-terminus (17,18).  Another difference between the halves was revealed by 
the crystal structure - a nucleotide-binding site near the N-terminus, distal from the 
equivalent active site (Fig. 1.2). 
Although it has been determined that only one molecule of Glu-6-P binds to HKI 
under physiological concentrations (19-21), mutational studies have shown that Glu-6-P is 
capable of inhibiting HKI when binding to either of the two halves of the enzyme (22,23).  
Only mutations in both sites can eliminate Glu-6-P-induced inhibition (23).  A truncated 
form of the enzyme, containing only the C-terminal half, exhibits the same inhibitory 
properties as the full-length protein (24).  This indicates that Glu-6-P likely inhibits HKI by 
binding to the C-terminal half (24).  Another mutant, α+2, that decouples the two halves and 
eliminates the communication across the N-/C-terminal half interface of HKI by a lengthened 
connecting helix, also supports this hypothesis (unpublished). 
In terms of the association of HKI with the mitochondrial membrane, HKI has been 
shown to associate specifically with the mitochondrial membrane protein porin through co-
localization studies (25,26).  Porin is known to form a complex with the adenine nucleotide 
translocase, where ATP exits the mitochondria and ADP enters 
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Figure 1.1.  X-ray crystal structure of HKI.  Glucose 6-phosphate molecules are shown in 
dark gray (23) 
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Figure 1.2.  X-ray crystal structure of HKI complexed with ADP and glucose and glucose 6-
phosphate (17). 
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(25,26).  This location on the mitochondrion would give HKI a competitive advantage to 
intra-mitochondrially generated ATP (Figure 1.3) relative to other cytosolic 
transphosphorylases (10).  There is evidence that the hydrophobic N-terminal tail of HKI 
inserts into the mitochondrial membrane, however, the specific interactions between porin 
and HKI have not been determined (27).  Porin, the adenine nucleotide translocase and a 
number of other proteins in the inner mitochondrial membrane, comprise the permeability 
transition pore, or PTP (28,29).   Opening of the PTP results in loss of membrane potential, 
organelle swelling, and cytosolic acidification (28,29).  One of the early signals of apoptosis 
is the passage of cytochrome c through the channel which in turn leads to the activation of 
the caspase family of proteases and ultimately results in the cell’s destruction (30-32).  HKI 
has been shown to prevent the passage of cytochrome c when bound to the PTP (7).  For this 
role, hexokinase I was given the nickname “guardian of the mitochondria” (33).   
Glucose 6-phosphate is not only capable of inhibiting the enzyme; it also regulates 
the cellular location of HKI (10).  Rose and Warms showed in 1967 that Glu-6-P released 
HKI from the mitochondria (10).  The presence of magnesium or inorganic phosphate can 
antagonize Glu-6-P-induced release from the membrane (10).  The mechanism by which 
Glu-6-P releases HKI is unknown, but it may be related to a conformational change induced 
by binding of the inhibitor (34).  Because of the dual roles reported for Glu-6-P, we 
hypothesize that each binding site may have a separate function: either inhibition or the 
release of HKI from the mitochondrion. 
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Figure 1.3.  Proposed model for HKI-PTP interaction.  Hexokinase I is shown to interacting 
with the outer mitochondrial membrane protein porin (VDAC) where ATP exits the 
mitochondria.  The adenine nucleotide transolocator protein (ANT) is shown in the 
inner mitochondrial membrane transporting ATP from the F0F1 ATP synthase in the 
mitochondrial matrix.  This figure was published by Gottlob et al. in 2001 (5).   
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Nucleoside triphosphates have also been shown to effectively remove HKI from the 
mitochondrial membrane (10).  There is some evidence that this mechanism of release is 
distinct from that of glucose 6-phosphate-induced release ().  This includes the inability of 
ATP to bind in the same location as Glu-6-P and differences in the amount of HKI released 
by the two releasing agents (10).  Other nucleoside triphosphates, CTP, GTP, UTP and ITP, 
which are not substrates of HKI, are also capable of removing the enzyme from the 
membrane (10).  Because of this, the C-terminal half may not be responsible for this 
phenomenon.  The nucleotide binding site near the N-terminus is a likely candidate with 
unknown specificity for nucleotides and its proximity to the membrane binding helix (17,18). 
Nemat-Gorgani and Wilson reported in 1985 that acidic phospholipids inhibited rat 
brain hexokinase by binding to the nucleotide binding site (35).  It has also been reported that 
washing HKI-laden mitochondria with phospholipids resulted in a higher percentage of HKI 
release from the membrane (36).  It is possible that the phosphorous head group of the lipid is 
binding in the pocket as the phosphoryl-group of the nucleoside triphosphate in the N-
terminal half nucleotide binding pocket. 
Recombinant HKI and mitochondrial binding/release—Recombinant HKI had been 
found to be lacking the N-terminal tail that is critical for binding to the mitochondrial 
membrane (15).  Minimizing the time from cell lysis to obtaining purified enzyme is 
absolutely crucial in preventing the limited proteolysis likely causing this problem.  Because 
of this, a new construct of HKI containing a C-terminal 10x polyhistidyl tail was created.  
Using Nickel-nitrilotriacetic acid-agarose (NiNTA) resin, purification time has been 
dramatically reduced and this purification has resulted in a construct that has an intact N-
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terminus with an N-formylated methionine as the initial residue.  The histidine-tagged 
protein has been found to have similar kinetic properties to the untagged wild-type enzyme. 
Previous mutational studies have found mutations in each of the glucose 6-phosphate-
binding pockets that can preclude Glu-6-P association (22,23).  The mutations are 
Thr232→Ala and Thr536→Ala and disallow binding of Glu-6-P to the N- and C-terminal 
halves respectively.  Glu-6-P release experiments should show a difference in the I0.5 value 
(amount of inhibitor required to remove half of the HKI protein) if the protein has a specific 
site responsible for releasing the enzyme in the presence of glucose 6-phosphate.  Since HKI 
has a “fail-safe” mechanism in kinetic studies (Glu-6-P binding to either site is capable of 
inhibiting the enzyme), either site may be capable of releasing the protein from the 
membrane.  The mutant α+2 was also be tested in this system to support the effect of Glu-6-P 
binding to either of the halves.  This mutant essentially turns the active C-terminal half into a 
reporter or the N-terminal half by separating the halves and eliminating communication 
across the allosteric interface.  If the N-terminal half is responsible for Glu-6-P-induced 
release, the I0.5 value should be nearly equal to the I0.5 value for the wild-type enzyme.  
Conversely, the α+2 mutant would be very difficult to remove from the membrane if the C-
terminal half contains the responsible Glu-6-P-binding site.  Finally, the combination 
α+2/Thr232→Ala mutant should be nearly impossible to remove from the membrane by Glu-
6-P because neither half would have a viable glucose 6-phosphate-binding site.  In either 
case, this series of mutations should give a clear picture as to the mechanism behind the 
release of HKI from the mitochondria due to Glu-6-P addition. 
Nucleotide-induced release of HKI from the mitochondrial membrane— It has been 
reported that nucleotides induce the release of HKI from the mitochondrial membrane (10), 
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however the mechanism through which release occurs has not been determined.  Previous 
experiments with HKI and ATP-induced release were done at a single concentration of 
ligand (10).  This gives no insight as to the model of release that can be observed.  The same 
procedures for loading and releasing HKI from the mitochondrial membrane can be 
employed, substituting ATP for Glu-6-P.  From the release curve generated, we were able to 
determine that ATP-induced release follows a simpler model compared to Glu-6-P-induced 
release. 
The role of the nucleotide binding site in the N-terminal half of HKI has not been 
addressed in previous studies of any kind.  It has been proposed by Rosano et al. (18), that 
the N-terminal half site is responsible for the ATP-induced release from the mitochondrial 
membrane, but it was not until the production of the recombinant full-length construct with 
intact N-terminus that this hypothesis could be tested.  The same techniques used in 
determining the site of Glu-6-P-induced mitochondrial release were employed to determine 
which ATP site is involved.  Mutations that can preclude ATP binding to this site were 
included in determining the specific site responsible, (N-terminal half nucleotide, N-terminal 
half Glu-6-P or C-terminal half nucleotide binding sites) for nucleotide-induced release of 
HKI from the mitochondria.  Through this mutational analysis, we have determined that 
mutation in any of the potential nucleotide binding sites make the protein more difficult to 
remove from the mitochondria, but changes in the I0.5 values were not significant, leading us 
to believe that ATP was effecting porin or the mitochondrial membrane and not HKI.   
The role of the N-terminal half nucleotide binding site— Very little is known about 
the N-terminal half nucleotide binding site.  In 1969, solution kinetics studies showed that 
ADP inhibition of HKI was noncompetitive relative to ATP, but the location of the allosteric 
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site was never identified.  The crystal structures produced in 2000, provided the location of a 
nucleotide binding site (17), but the nucleotide binding site and the allosteric site proposed 
had never been tied together experimentally.  The same set of mutations produced in the 
previous study was applied to ADP inhibition studies similar to the work done by Ning, et al 
(37).  Through these experiments, it has been determined that the N-terminal half nucleotide 
binding site and the allosteric site from kinetics studies are equivalent.  Finally, we showed 
that there is no synergism between the inhibitors (Glu-6-P and ADP).   
Thesis Organization 
This thesis contains five chapters.  A literature review with general information on 
Type I hexokinase is contained in Chapter I.  The second chapter is a paper that has been 
published in The Journal of Biological Chemistry.  A recombinant form of HKI was created 
that allows for a more rapid purification and is capable of binding to the mitochondrial 
membrane.  With this new construct the release induced by glucose 6-phosphate was studied 
and a mechanism for release has been proposed.  It was shown that N-terminal half of HKI 
was the glu-6-P binding site responsible for regulating the protein’s cellular location.   
ATP and other nucleotides were shown to release HKI from the mitochondrial 
membrane in previous experiments.  Using the techniques from Chapter II, ATP release was 
studied in conjunction with mutations in all potential nucleotide binding sites.  It is clear 
from the experiments that the ATP release mechanism is distinct from the glu-6-P 
mechanism.  Additionally, it appears that ATP is not effecting HKI but possibly porin or 
another portion of the mitochondrial membrane.   
Early solution kinetics studies showed that ADP inhibition was mixed in relation to 
ATP, leading to the proposal of the existence of an allosteric binding site distinct from the 
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active site.  X-ray crystal structures showed a nucleotide binding site near the N-terminus, 
but work was never done to prove that this site is the allosteric site.  Chapter IV contains a 
series of mutations in potential nucleotide binding sites that prove the site of allostery is the 
N-terminal nucleotide binding site.   
General conclusions to the work appearing in the previous chapters and potential 
future directions for work with hexokinase are described in Chapter V.   
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Abstract 
One molecule of glucose 6-phosphate inhibits brain hexokinase (HKI) with high affinity by 
binding to either one of two sites located in distinct halves of the enzyme. In addition to 
potent inhibition, glucose 6-phosphate releases HKI from the outer leaflet of mitochondria; 
however, the site of glucose 6-phosphate association responsible for the release of HKI is 
unclear. The incorporation of a C-terminal polyhistidine tag on HKI facilitates the rapid 
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purification of recombinant enzyme from Escherichia coli. The tagged construct has N-
formyl methionine as its first residue and has mitochondrial association properties 
comparable with native brain hexokinases. Release of wild-type and mutant hexokinases from 
mitochondria by glucose 6-phosphate follow equilibrium models, which explain the release 
phenomenon as the repartitioning of ligand-bound HKI between solution and the membrane. 
Mutations that block the binding of glucose 6-phosphate to the C-terminal half of HKI have 
little or no effect on the glucose 6-phosphate release. In contrast, mutations that block glucose 
6-phosphate binding to the N-terminal half require ~7-fold higher concentrations of glucose 
6-phosphate for the release of HKI. Results here implicate a primary role for the glucose 6-
phosphate binding site at the N-terminal half of HKI in the release mechanism.  
 
Introduction 
Brain tissue relies almost exclusively on glucose as its source of energy. 
Approximately 25% of circulating blood glucose and 20% of consumed oxygen is utilized by 
the brain, an organ that constitutes less than 2% of the human body mass (1). Although four 
isozymes of hexokinase (ATP:D-hexose 6-phosphotransferase (2.7.1.1)) are present in 
mammals, brain tissue contains only a single isozyme, hexokinase I (HKI)2 (2-4). HKI is 
arguably the "pacemaker of glycolysis" in the brain and red blood cell (5), and thus, its 
mechanism of action and its molecular regulation is of overriding significance. Glucose 6-
phosphate (Glu-6-P) is not only a potent inhibitor of HKI at physiological concentrations, but 
it can release HKI from brain mitochondria (6). The HKI-release function of Glu-6-P may be 
the first step in an enzyme degradation pathway (6) and/or a process linked to apoptosis (7-
10).  
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X-ray crystallographic structures of HKI are available (11-15). The wild-type enzymes are 
dimers of 100 kDa subunits (12), but an engineered mutant HKI crystallizes as a monomer, 
adopting a conformation similar to that of the subunit of the dimer (14). Hexokinase 
associated with the mitochondrial membrane may be a mixture of monomeric and tetrameric 
states (6, 16), and possibly in one or both of these states, HKI could be associated with 
mitochondrial porin (16). The enzyme is strongly inhibited by one of its reaction products, 
Glu-6-P, and this inhibition can be reversed by physiological concentrations of inorganic 
orthophosphate (6). In fact, HKI may be inhibited 95-98% in vivo (5). Mitochondrial 
association requires the first 15 amino acid residues at the N terminus of HKI. These residues 
are hydrophobic or without formal electrostatic charge, and could adopt a helical 
conformation (6, 17, 18). Mitochondrial association gives HKI a competitive advantage 
relative to cytosolic transphosphorylases for mitochondrially synthesized ATP (13). It is now 
known that HKI binds to the mitochondrion in proximity to porin and the translocator protein 
responsible for the ADP/ATP transport (6, 17, 18).  
The mechanism of Glu-6-P regulation of HKI has been a focal point of research from our 
laboratory since 1962 (20). In 1951, Weil-Mahlerbe and Bone (21) reported Glu-6-P as a 
noncompetitive inhibitor of ATP (21). On the basis of fundamental differences in the HKI 
recognition of glucose and Glu-6-P analogs, Crane and Sols (22) concluded Glu-6-P acted as 
an allosteric inhibitor. In 1962, Fromm and Zewe (20) demonstrated that Glu-6-P is, in fact, a 
competitive inhibitor of ATP and linear noncompetitive inhibitor of glucose, a finding 
subsequently confirmed by a number of investigators (3, 23-27). Glu-6-P, acting as an 
allosteric inhibitor, is not in conflict with kinetics. Indeed, competitive inhibition merely 
demands mutual exclusivity in the binding of inhibitor and substrate to HKI (28).  
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Problems in understanding the mechanism of Glu-6-P regulation of HKI have arisen over 
apparent contradictions regarding the number of Glu-6-P binding sites and their location. 
Equilibrium binding experiments from several groups show but one high affinity binding site 
for Glu-6-P on HKI, and yet all relevant crystal structures of HKI reveal bound molecules of 
Glu-6-P and glucose at the N- and C-terminal halves of the enzyme (12-15). Wilson (1, 29-
33), a proponent of an inhibitory site for Glu-6-P at the N-terminal half, was among the first 
to show Glu-6-P inhibition of the truncated C-terminal half of HKI (34). Data from several 
groups are in agreement: the kinetics of Glu-6-P inhibition of the truncated enzyme (C-
terminal half) are virtually identical to those of full-length HKI. Several mutations in the Glu-
6-P binding site in the N-terminal half of HKI eliminated Pi relief of Glu-6-P inhibition, but 
had no effect on Glu-6-P inhibition (35). Mutations of the Glu-6-P binding site in the C-half 
of HKI, however, also had no effect on Glu-6-P inhibition; only mutations at both Glu-6-P-
binding sites resulted in the loss of inhibition (36). To reconcile these observations, Liu et al. 
(36) suggested a coupling mechanism between the N- and C-terminal halves of HKI that 
mediate antagonistic interactions between the two Glu-6-P binding sites. Different functional 
contexts for HKI (as a monomer in solution, and quite possibly both a monomer and an 
oligomer on the mitochondrion) may favor different inhibitory mechanisms.  
In addition to its role as a potent inhibitor of HKI, Glu-6-P is also capable of releasing 
mitochondrial-bound HKI (6). The molecular mechanism responsible for the release of HKI 
by Glu-6-P is unknown; however, it may be related to the conformational state of HKI 
observed with bound Glu-6-P (37). In particular, we were interested in the extent to which 
each Glu-6-P binding site participates in the release of HKI from the mitochondrion. To 
address this issue, we prepared mutants of HKI in which the two Glu-6-P binding loci were 
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modified to preclude Glu-6-P binding. The results here show unequivocally that Glu-6-P 
binding to the N-terminal half is responsible for the release of recombinant human HKI from 
the mitochondrion. 
Materials and Methods. 
Materials—ATP, NADP, Glu-6-P, glucose 1,6-bisphosphate, deoxyribonuclease (DNase I), 
leupeptin, and phenylmethylsulfonyl fluoride were from Sigma. Kanamycin sulfate was 
purchased from Invitrogen. DEAE HPLC resin was a product of Tosohaas. Nickel-
nitrilotriacetic acid-agarose resin and Rosetta (DE3) competent cells were from Novagen. 
Glucose-6-phosphate dehydrogenase was obtained from Roche Molecular Biochemicals. 
Isopropyl 1-thio-β-D-galactopyranoside was from Anatrace. The HKI inhibitor, 1,5-
anhydroglucitol 6-phosphate (AnGlu-6-P), was available from a previous study (36). 
Oligonucleotide synthesis and DNA sequencing were performed at the Iowa State University 
DNA Sequencing and Synthesis Facility.  
Construction of Wild-type Hexokinase and Mutant Plasmids—Full-length human brain 
hexokinase had been cloned into pET-11a in a previous study (38). From this construct, the 
gene was cloned into pET-24b, which contains a His6 tail at the C terminus of the insertion 
site between the NdeI site and the EcoRI site, to produce pET-24b-HKI. The plasmid was 
then modified to add four additional histidine residues to increase the expressed affinity of 
the protein toward nickel-nitrilotriacetic acid-agarose. This modification was made through 
mutagenesis using PCR with the forward primer 5'-CAAGCTTGCGGCCGCACTCGAGC 
ACCACCACCACCACCACCACCACCACCACTGAGATCC-3' and its reverse 
compliment. The forward primers for the directed mutations Thr232→Ala and Thr536→Ala 
were 5'-GAAGTCGGCCTGATCATCGGCGCTGGCACCAATGCTTGCTACAT-3' and 5'-
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GCCCTGGATCTTGGAGGAGCCAATTTCCGTGTGCTGCTGGTGAAAATCC-3', 
respectively (modified nucleotides underlined). A mutant, α+2 HKI, with an extended 
connecting helix between the N- and C-halves of the enzyme, was made through two rounds 
of PCR mutagenesis, adding seven amino acids, or approximately two turns of α-helix, after 
position 466 of HKI. The first round added four amino acid residues, using the forward 
primer 5'-
GCCTACCGCTTGGCCGAGCAGCACATGAACCTGCACCGGCAGATAGAGGAGACC
CTG-3'. The second primer inserted the remaining nine nucleotides with forward primer 5'-
TGGCCGAGCAGCACATGAACCTGGCGGAACAGCACCGGCAGATAGAGGAGACC
CTG-3' (the inserted codons are underlined). The Thr232→Ala/α+2 combination mutant 
employed the above Thr232→Ala primers on the α+2 construct. The entire gene of each 
mutant as well as that of the wild-type enzyme was verified by sequencing.  
Expression and Purification of Wild-type and Mutant Hexokinases—Wild-type or mutant 
pET-24b-HKI plasmids were transformed into Rosetta (DE3) cells, which were then grown in 
LB media at 37 °C to an OD of 1.0. The temperature was then lowered to 16 °C and isopropyl 
1-thio-β-D-galactopyranoside was added to a final concentration of 0.2 mM. Cells were 
harvested 16-20 h after induction and resuspended in a lysis buffer of 25 mM NaH2PO4, pH 
8.0, 300 mM NaCl, 2 mM glucose, 5 mM imidazole, and 1 mM dithiothreitol. In addition to 
the lysis buffer, 50 µg/ml DNase I, 5 mM MgCl2, 20 µg/ml leupeptin, and 1 mM 
phenylmethylsulfonyl fluoride were added to the suspension. The cells were then lysed using 
a French press and centrifuged. The supernatant fluid was applied to a nickel-nitrilotriacetic 
acid-agarose column. The column was washed with 25 mM NaH2PO4, pH 8.0, 300 mM 
NaCl, 2 mM glucose, 40 mM imidazole, and 1 mM dithiothreitol, and then eluted with the 
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same buffer containing 250 mM imidazole. The eluate was then dialyzed overnight in 25 mM 
KH2PO4/K2HPO4, pH 7.5, 2 mM glucose, and 2 mM β-mercaptoethanol. The protein was 
then applied to a preparative DEAE HPLC column as described previously (35). The Iowa 
State University Protein Facility performed N-terminal sequencing on purified HKI. Prior to 
N-terminal sequencing, the protein was bound to a ProSorb sample preparation cartridge 
(PerkinElmer Life Sciences) containing a polyvinylidene difluoride membrane. The N 
terminus was deblocked by soaking the HKI-coated membrane in 0.6 M HCl overnight (39).  
Pig Liver Mitochondria Purification—Pig livers were obtained from the Iowa State 
University Meats Laboratory shortly after slaughter. Mitochondria were purified by the 
procedure of Graham (40). Mitochondria were resuspended in the storage buffer with two 
modifications: no potassium phosphate was added, and the solution contained 5% Me2SO, 
which acts as a cryoprotectant (41). The mitochondria were then flash frozen in dry ice-
ethanol and stored at -80 °C.  
The HKI Activity Assay—Hexokinase activity was measured using the glucose-6-phosphate 
dehydrogenase-coupled spectrophotometric assay at pH 8.0 (20). Hexokinase concentrations 
were determined by the Bradford method with bovine serum albumin as the standard (42). 
Initial rate data were analyzed using the computer program GraFit (43). For kinetic 
measurements of HKI on the mitochondrial membrane, whole mitochondria with bound 
hexokinase were added to the assay mixture and velocities were measured using the 
spectrophotometer. These data were fit by nonlinear least squares (using GraFit) to models 
described under "Results."  
Circular Dichroism Spectra—Circular dichroism spectra were measured using a Jasco J710 
circular dichroism spectrometer. The data were collected at room temperature between 200 
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and 260 nm. The concentration of HKI used in these measurements was 0.2 mg/ml in 2 mM 
HEPES, pH 7.8, with 0.2 mM glucose and 2 mM β-mercaptoethanol.  
Mitochondrial Binding and Release—Prior to carrying out the binding experiments, HPLC-
purified HKI was passed over a Sephadex G-50 column (Sigma) for desalting and to 
equilibrate the enzyme solution with the mitochondrial binding buffer, and then diluted to 2 
mg/ml. The mitochondrial binding buffer contains 250 mM sucrose, 5 mM glucose, 5 mM 
MgCl2, and 5 mM HEPES, pH 7.4. Mitochondria were diluted into this buffer to a 
concentration of 3 mg/ml, wet weight. Purified HKI and mitochondria were mixed and 
allowed to stand for 90 min on ice, and then centrifuged at 10,000 x g for 8 min. Unbound 
HKI in the supernatant fluid was decanted. Pelleted mitochondria were resuspended in 
mitochondrial binding buffer, less the MgCl2, and re-centrifuged. This wash step was 
repeated, after which pelleted mitochondria were resuspended in the mitochondrial binding 
buffer (MgCl2 absent) and assayed for HKI activity (MgCl2 included with ATP).  
HKI release from the mitochondria was performed as follows. HKI was bound to 
mitochondria as above, and then resuspended in a release buffer containing 250 mM sucrose 
and 5 mM HEPES, pH 7.4. 100-µl aliquots of this solution were distributed to plastic 
microcentrifuge tubes, to which Glu-6-P at various concentrations was added and allowed to 
sit for 30 min at room temperature. The mitochondria were pelleted by centrifugation. HKI 
solubilized by Glu-6-P was removed by decanting the supernatant liquid. The mitochondrial 
pellet was resuspended in 250 mM sucrose, 5 mM glucose, and 5 mM HEPES, pH 7.4, and 
centrifuged again. After discarding the supernatant fluid, pelleted mitochondria were 
resuspended, and then assayed for hexokinase activity. For the mitochondrial release 
experiments, data for mutant HKI and wild-type HKI data were collected in parallel. 
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Results 
HKI Construction, Purification, and N-terminal Sequencing—Purified recombinant HKI 
used in crystallographic studies was a mixture of proteins beginning with either residue 10 or 
12 of the translated DNA sequence (12). As the initial 10-12 residues are absolutely crucial 
for mitochondrial binding (44), the purified recombinant system used in crystallography can 
provide no information regarding mitochondrial association and release phenomena. With the 
intent of recovering full-length HKI, a His-tagged HKI-pET-24b construct was prepared to 
facilitate rapid purification of recombinant enzyme. An initial construct with His6 at the C 
terminus of HKI bound poorly to the nickel-nitrilotriacetic acid-agarose, but a 10-histidyl tag 
resulted in a construct with strong binding properties. After nickel-nitrilotriacetic acid-
agarose and DEAE chromatography, protein purity was at least 95% as judged by SDS-
polyacrylamide gel electrophoresis (data not shown). N-terminal sequencing of the purified 
protein returned no signal above background, indicating an N terminus chemically blocked 
from participation in the Edman degradation reaction. Deblocking of the N-formyl group in 
0.6 M HCl was successful as evidenced by a clean amino acid sequence (MIAAQ) from five 
cycles of Edman degradation.  
Rationale for the Selection of Mutants—As shown previously by Liu et al. (36), the mutation 
Thr536→Ala eliminates AnGlu-6-P inhibition of C-terminal half of HKI (TABLE ONE). The 
mutation of Thr232→Ala eliminates Pi relief of AnGlu-6-P inhibition in the full-length HKI 
(35). Either mutation alone has no effect on AnGlu-6-P inhibition of full-length HKI, but 
when combined, the resulting mutant enzyme is not sensitive to AnGlu-6-P (36). Hence, 
AnGlu-6-P can bind to the N-terminal and/or C-terminal halves of HKI, in each case causing 
potent inhibition of catalysis by kinetic mechanisms that are competitive with ATP and 
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noncompetitive with glucose (36). Equilibrium binding studies in the presence and absence of 
glucose, however, indicate only one bound Glu-6-P molecule per HKI molecule (45-47). 
Hence, the two Glu-6-P binding sites in the separate halves of HKI are coupled, allowing 
Glu-6-P to bind at only one of its two potential binding sites. The mutation at position 536 
blocks Glu-6-P binding to the C-terminal half, whereas the mutation at position 232 blocks 
Glu-6-P binding to the N-terminal half. 
The α+2 mutation inserts a repeat of seven consecutive residues after position 466. The 
insertion is at the middle of the transition helix between the N- and C-terminal halves of HKI, 
and should add approximately two full turns to that α-helix. The insertion should separate the 
two halves of the α+2 enzyme by an additional 11 Å while maintaining the relative 
orientation of the two halves observed in wild-type HKI. The mutation disrupts the coupling 
between Glu-6-P binding sites of the N- and C-terminal halves, i.e. inhibition of the α+2 
construct by AnGlu-6-P is competitive with ATP and noncompetitive with glucose, and as 
potent as AnGlu-6-P inhibition of the wild-type enzyme (TABLE ONE). Unlike the wild-
type enzyme, however, the mutation of Thr536 to alanine in the α+2 construct abolishes 
AnGlu-6-P inhibition. Hence, the coupling mechanism between the N- and C-terminal halves 
observed in wild-type HKI no longer operates in the α+2 construct. Glu-6-P, by binding to 
the C-terminal half of HKI, could conceivably influence the conformation of the N-terminal 
half of the wild-type system by way of the N-half/C-half coupling mechanism, but that 
influence would be reduced severely or eliminated altogether in the α+2 construct. 
Kinetic Analysis of Wild-type and Mutant Enzymes—Kinetic parameters of the His-tagged 
construct are comparable with those reported for non-tagged HKI (TABLE ONE). The small 
disparities between constructs in TABLE ONE are probably because of the His tag at the C 
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Table I. 
Kinetic parameters for wild-type and mutant HKI constructs. 
Enzyme kcat KmATP KmGlc KiAnG6P 
 sec-1 mM µM µM 
Wild-type 75±4 1.5±0.2 62±3 17±2 
Wild-type, His-tagged 93±3 1.3±0.4 76±5 38±4 
Thr232→Alaa,c 70±2 0.81±0.04 42±2 84±5 
Thr536→Alab,c 9.7±0.1 1.80±0.06 43±1 25±2 
Thr232→Ala/Thr536→Alab,c 17.3±0.7 0.90±0.03 61±5 NDd 
Truncated C-terminal halfb,c 45.6±0.9 0.5±0.1 52±4 25±2 
Truncated C-terminal half/ 
Thr536→Alab,c 
11±1 0.37±0.03 57±3 NDd 
α+2c 47±1 1.9±0.1 48±3 28±1 
α+2/Thr232→Alac 56±1 1.77±0.09 180±10 21.7±0.9 
α+2/Thr536→Alac 1.11±0.02 1.13±0.05 180±30 NDd 
aFrom reference (35). 
bFrom reference (36). 
cWithout His tag. 
dNo inhibition by AnG6P at a concentration of at least 500 µM. 
 
terminus of HKI. AnGlu-6-P, which mimics the inhibition of Glu-6-P but is not a substrate 
for the coupled assay (48), is a competitive inhibitor with respect to ATP and noncompetitive 
inhibitor with respect to glucose. The kinetic mechanisms of inhibition for the His-tagged 
construct are identical to those reported for the non-tagged enzyme.  
Mitochondrial Binding of HKI—Appropriately prepared liver mitochondria are devoid of 
native hexokinase activity (49). His-tagged HKI, bound to mitochondria, increased 
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hyperbolically with HKI concentration (Fig. 1). The binding response curve of His-tagged 
HKI is comparable with that of the native enzyme (16). At saturation, the specific activity of 
bound His-tagged HKI is 101 ± 5 milliunits/mg of mitochondria, wet weight.   
 
 
 
 
Fig. 1  Recombinant human HKI binding to pig liver mitochondria.  Binding was done in the 
presence of 250 mM sucrose, 5 mM glucose, 5 mM MgCl2 and 5 mM HEPES, pH 7.4.  Each 
fraction contained 0.32 mg mitochondria (wet weight).  A hyperbolic saturation curve is fit to 
the data with a goodness-of-fit of 1%.   
 
 
Glu-6-P-induced Release of Wild-type and Mutant HKI from Mitochondria—Several models 
were considered to account for the observed release of wild-type and mutant HKI from 
mitochondria in response to increasing concentrations of Glu-6-P. The models fall into two 
general categories: (i) equilibrium models in which Glu-6-P, HKI (or a HKI mutant), and 
mitochondrial binding sites are in equilibrium or (ii) kinetic trap models in which a fraction 
of the bound HKI is non-dissociating relative to the incubation time of the experiment (1 h). 
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Incubation times of 20 and 40 min produced release curves identical to that of 30 min, 
indicating an equilibrium process as was found by Rose and Warms (6). Ultimately, the 
simplest equilibrium model that can account for all observed phenomena associated with the 
Glu-6-P release of wild-type and mutant HKI from mitochondria is shown in Scheme I.  
E + 1M = E1M, K1 = [E1M]/[E][1M] 
E1M + I = E1MI K1i = [E1MI]/[E1M][I] 
E + I = EI  Ki = [EI]/[E][I] 
EI + I = EI2  Kii = [EI2]/[EI][I] 
 Scheme I 
 
In Scheme 1, K1, K1i, Ki, and Kii are association constants, E represents wild-type or mutant HKI, and 
1M represents the concentration of a uniform class of mitochondrial binding sites for E. In Scheme 1 it 
is assumed that the formation of the quaternary complex E1MI2 is precluded, i.e. binding of Glu-6-P to 
the HKI release site prevents binding of the enzyme to the mitochondrion.  
The model can be generalized for n different types of mitochondrial binding sites, for instance, 
1M,2M, 3M,...nM, by adding equilibrium relations in pairs comparable with the first two relationships 
above. The form of the mathematical equation used in data analysisis the same regardless of the 
number of distinct types of binding sites for E on the mitochondria. Using the equations above, the 
fraction of mitochondrial bound enzyme R as a function of [I] (concentration of Glu-6-P) is as 
follows. 
R([I]) = {K1[1M] + K1[1M]K1i[I]}/{1 + K1[1M] + K1[1M]K1i[I] + Ki[I] + KiKii[I]2}            (1) 
 The velocity of the enzyme reaction is assumed directly proportional to the fraction of bound 
enzyme. Hence, the observed velocity depends on the concentration of I as follows, 
V([I]) = aR([I])                     (2) 
where a represents a proportionality constant with units of velocity. Equation 2 is of the general form, 
V([I])=a{b+c[I]}/{1+b+c[I]+Ki[I]+KiiKi[I]2}         (3) 
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where b = [E1M]/[E] and c = [E1MI]/[E][I]. Equilibrium models that include multiple types of binding 
sites for E on the mitochondria retain the original definition of a, but parameters b and c take on new 
meanings. For instance, b = {[E1M] + [E2M] + [E3M]+... +[EnM]}/[E] and c = {[E1MI] + [E2MI] + 
[E3MI]+... +[EnMI]}/[E][I] for a model with n different types of mitochondrial binding sites for E.  
Equation 3 accounts for trends exhibited by the data. (i) In the absence of Glu-6-P, the concentration 
of free enzyme is small relative to the concentration of bound enzyme. Hence b must be large relative 
to unity, so that at I = 0, V (0) = a{b/(b + 1)} = ~a. (ii) If Kii is 0, then at high concentrations of Glu-6-
P, V([I]) = ~a{c/(c + Ki)}. Hence, Equation 3 places a limit on the Glu-6-P release of bound enzyme. 
If Kii is not 0, then an infinite concentration of Glu-6-P would cause full release. As demonstrated 
below, the Kii term is significant, but small relative to c and Ki for the wild-type enzyme. In contrast, 
Kii is indistinguishable from 0 for all mutant constructs considered here.  
To compare the efficacy of Glu-6-P release for the various constructs of HKI, we define I0.5, the 
concentration of Glu-6-P necessary to release one-half of the bound fraction in the absence of an EI + 
I = EI2 equilibrium. More precisely, we define V0.5 as follows.  
V0.5 = (a/2){[b/(b+1)] – [c/(c+Ki)]}                             (4) 
Using this definition of V0.5 in Equation 3 (with Kii = 0) we solve for I0.5, 
I0.5 = [V0.5 – b(a – V0.5)]/[c(a – V0.5) – KiV0.5]             (5) 
Equation 2 was fit to data for wild-type and mutant forms of HKI using non-linear least squares. 
Correlations between Ki, b, and c preclude the refinement of all three as independent parameters. 
Fortunately, equilibrium binding experiments for the native enzyme provide a value for Ki (<1 µM-1) 
(45). Moreover, goodness-of-fit values and values of V0.5 and I0.5 do not vary significantly with Ki over 
the range 0.1-10 µM-1. Hence, V0.5 and I0.5 serve well in a direct comparison of data sets. In contrast, 
fitted values for parameters b and c scale proportionately with Ki. The choice of Ki, which is at best an 
approximation for some of the mutant constructs, biases the fitted values for parameters b and c, 
making these parameters unsuitable for the comparison of different data sets. For all mutant 
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constructs, the refined value of Kii is indistinguishable from 0. Hence, for all mutant enzymes, Kii was 
fixed to 0, with only a, b, and c as adjustable parameters. In contrast, the Kii value for the wild-type 
enzyme differed significantly from 0, necessitating fits with the full four-parameter model.  
Results of the analysis appear in TABLE TWO. Each release experiment for a mutant enzyme was 
done in parallel with an experiment for the wild-type enzyme. I0.5 values for four separate 
preparations of recombinant wild-type enzyme, using the same preparation of mitochondria, ranged 
from 24 to 50 µM. A plot of the wild-type data sets (Fig. 2) reveals similar curves displaced relative to 
each other. These curve displacements reflect systematic differences between preparations of wild-
type enzyme, the origin of which is unclear. Curve displacements are not correlated with time as 
would be expected for an aging phenomenon associated with the mitochondria. Differences in I0.5 and 
V0.5 for the four wild-type data sets, however, are not significant relative to the standard deviations in 
their values. The average I0.5 value over the four experiments for recombinant wild-type HKI is 35 µM 
with a root mean square deviation of ~10 µM. The mutation of Thr232 to alanine increases I0.5 by 7-
fold over its corresponding wild-type value and 5-fold over the average I0.5 value (TABLE TWO and 
Fig. 3). The Thr232→Ala mutation in the α+2 construct increases the I0.5 value 13-fold relative to the 
average and corresponding wild-type values. In contrast, the I0.5 value of Thr536→Ala HKI does not 
differ significantly from that of the wild-type enzyme, and the difference in I0.5 values of the wild-type 
and the α+2 construct is of borderline significance. Limiting levels of release associated with the 
binding of a single molecule of Glu-6-P vary from 70 to 80% for the mutant constructs, and 50-60% 
for the wild-type experiments. The highest concentrations of Glu-6-P (6 mM), however, ultimately 
cause levels of release for the wild-type enzyme comparable with those of the mutant constructs. 
Discussion 
The present study is the first application of a recombinant HKI in the investigation of 
mitochondrial association and release phenomenon. The addition of the polyhistidyl tag to the 
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Table II. 
Fitted parameters for G6P-induced release of mitochondrial HKI.  Parameters a, b, c, Kii, and I0.5 are 
defined in the Results section.  Standard deviations in the last significant digit are given in 
parentheses. 
HKI construct a b c Kii I0.5a 
Relative 
velocity 
at I0.5b 
Limiting 
release 
 µM s-1  µM–1 mM µM  %c 
α+2 0.2323(8) 71(1) 0.275(4) –e 57(1) 0.600(3) 78.4(2) 
Wild-typed 0.276(3) 50(4) 0.87(3) 1.66(2) 28(4) 0.72(1) 53.6(9) 
Thr232→Ala 0.241(5) 240(30) 0.43(4) –e 170(30) 0.65(2) 70(2) 
Wild-typed 0.225(5) 40(7) 0.73(6) 1.83(5) 24(6) 0.70(3) 58(2) 
Thr536→Ala 0.01104(3) 35.4(6) 0.419(4) –e 25.7(6) 0.634(3) 70.5(2) 
Wild-typed 0.364(8) 120(30) 1.3(2) 3.34(9) 50(20) 0.78(3) 43(3) 
α+2/Thr232→Ala 0.276(5) 590(60) 0.28(4) –e 460(60) 0.61(2) 78(2) 
Wild-typed 0.3213(5) 69.1(9) 0.965(4) 1.81(3) 35.7(7) 0.738(2) 50.9(1) 
aCalculated using Equation 5. 
bV0.5/a, where V0.5 is calculated from Equation 4. 
cPercent limiting release = 100x(1–V∞/a), where V∞=c/(c+Ki). 
dWild-type data collected in parallel with data for the mutant HKI immediately above it in the table. 
eFixed at 0. 
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Fig. 2  G6P-induced release of wild-type HKI release from pig liver mitochondria.  
Mitochondria with HKI bound were suspended in 250 mM sucrose, 5 mM glucose 
and 5 mM HEPES, pH 7.4, after exposure to varying concentrations of G6P.  Plotted 
here are relative velocities from the mitochondrion-bound HKI that remains after a 
30-minute incubation with G6P, the concentration of which is given as a base-10 
logarithm.  Each preparation of the recombinant wild-type enzyme was done in 
parallel with a specific mutant HKI as follows: the α+2 construct (♦), the 
Thr232→Ala mutant enzyme (◊), the Thr536→Ala mutant enzyme (■), and the 
α+2/Thr232→Ala mutant enzyme (□).  The solid lines represent fitted curves, using 
Equation 3 with parameters listed in Table II. 
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Fig. 3  G6P-induced release of wild-type and mutant HKIs from pig liver mitochondria.  
Mitochondria with HKI bound were suspended in 250 mM sucrose, 5 mM glucose and 5 mM 
HEPES, pH 7.4, after exposure to varying concentrations of G6P.  Plotted only are data from 
the concentration range 0–1 mM in G6P to focus on changes in relative velocity of greatest 
significance.  In each panel, data for wild-type recombinant enzyme (■) is presented along 
with data from a mutant HKI done in parallel: panel A, Thr232→Ala enzyme (♦); panel B, 
Thr536→Ala enzyme (▲); panel C, α+2/Thr232→Ala enzyme (◊); panel D, α+2 construct (□). 
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 C terminus of HKI facilitates rapid purification and minimizes the exposure of the enzyme to 
proteases from the Escherichia coli expression system. The protocol employed here results in 
recombinant enzymes with an N-formylated methionine taking the place of a presumed N-
acetyl group at the N terminus of native human HKI. (Native rat enzyme likely has an N-
acetyl group (44), and this is presumably a feature common to mammalian type I 
hexokinases.) The polyhistidyl-tagged wild-type enzyme binds to mitochondria in the 
presence of Mg2+, as reported for the native enzymes from several species (6, 50-52). The 
average I0.5 value reported here (35 µM) is comparable with that (~50 µM) estimated by Rose 
and Warms (6) for the release of native hexokinase from S-37 ascites mitochondria. 
Moreover, the percentage of released enzyme from mitochondria, as a function of Glu-6-P 
concentration, is nearly identical for the recombinant human and ascites systems (6). Glucose 
1,6-bisphosphate, like Glu-6-P, is a powerful inhibitor of HKI (24, 26, 53), and releases 
native hexokinase from the mitochondria of various rat tissues (54). Glucose 1,6-
bisphosphate also releases recombinant human HKI from porcine liver mitochondria, the 
release curve being qualitatively similar to that obtained with Glu-6-P (data not presented). 
Evidently, the C-terminal polyhistidyl tag and N-formyl methionine substitution does not 
alter mitochondrial binding properties, and have only a modest effect on kinetic parameters.  
The mitochondrial binding properties of the mutant enzymes studied here allow a definitive 
conclusion: a mutation that impairs Glu-6-P association with the C-terminal half has no 
significant effect on the property of HKI release from the mitochondrial membrane, whereas 
a mutation that impairs Glu-6-P association with the N-terminal half increases the I0.5 value 
by at least 5-fold. Evidently, the binding of Glu-6-P to the N-terminal half of HKI is primarily 
responsible for the release of HKI from the mitochondrial membrane. Conceivably, HKI may 
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partition between a soluble state with Glu-6-P bound to the N-terminal half and a 
mitochondrial-associated state with Glu-6-P bound to the C-terminal half. If so, Glu-6-P 
inhibition of mitochondrial-bound HKI would occur at the active site, whereas inhibition of 
soluble HKI would occur at the allosteric site. Whether the role of the Glu-6-P binding site at 
the N-terminal half is exclusively for the release of enzyme from mitochondria, as 
hypothesized by Arora et al. (55), or whether it also participates in the inhibition of catalysis 
both on and off the membrane is not settled by this or any other study.  
The α+2 construct decouples the N- and C-terminal halves of HKI. The mutation of Thr536 to 
alanine abolishes Glu-6-P inhibition in the α+2 construct, in contrast to the Thr536→Ala 
mutation in the wild-type system, which retains potent Glu-6-P inhibition (TABLE ONE). 
The I0.5 value for the α+2 construct is ~2-fold higher than that of the wild-type system 
(TABLE TWO). Moreover, the I0.5 value for the α+2/Thr232→Ala construct is again ~2-fold 
greater than that of the Thr232→Ala mutant enzyme. Although the differences (2-fold) are 
marginally significant, the trend is clear: the concentration of Glu-6-P necessary for the 
release of the α+2 construct is higher than for the release of the wild-type enzyme. A number 
of factors can in principle be responsible for this phenomenon, but the one known difference 
between the wild-type and α+2 constructs is the absence of a coupling mechanism between 
the N- and C-terminal halves for the latter system. Hence, the coupling mechanism could 
facilitate the release of wild-type HKI from mitochondria by Glu-6-P. Moreover, interactions 
between the N-terminal half and the mitochondrial membrane could be influenced by the 
conformational state of the C-terminal half.  
The model used in the analysis of release data assumes an equilibrium between membrane-
bound and soluble forms of the enzyme, as well as a single type of binding site on the 
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mitochondria. Release of hexokinase is limited in this simple model by the equilibrium 
constant that reflects the balance in free energies of the HKI·Glu-6-P complexes in solution 
and on the membrane. HKI leaves the membrane because conformational changes wrought 
by the binding of Glu-6-P increase the free energy of the mitochondrial bound state relative to 
that of the solution state. A kinetic model, however, can also account for a limiting release of 
HKI: some fraction of the total bound HKI could be "stuck" on the membrane, because of an 
extremely slow step in a distinct release mechanism. The kinetic model is unlikely because 
ATP rapidly releases 90% of bound hexokinase from ascites mitochondria (6), and various 
salts also release nearly all bound HKI (6, 56, 57). Hence, the limiting release of ~60% 
induced by Glu-6-P is most likely an equilibrium phenomenon.  
The assumption of a single type of mitochondrial binding site is not justified by data from 
other investigations, but as pointed out under "Results," the fitting equation is not altered by 
the inclusion of multiple types of membrane-binding sites. If only a single type of site were to 
exist, then mitochondria with retained HKI would again exhibit a 60% release when exposed 
to Glu-6-P solutions with no soluble enzyme. No additional release, however, has been 
observed in such experiments (56), and hence, any valid equilibrium model requires at least 
two kinds of binding sites on the mitochondria that recognize a single state of HKI or two 
different states of HKI that compete for a single type of mitochondrial binding site. Others 
(32) have recognized the necessity for at least two kinds of mitochondrial binding sites, but 
evidence also exists for multiple states of membrane-associated hexokinase. Indirect evidence 
from Rose and Warms (6) indicates releasable HKI is monomeric on the membrane and in 
solution, and results of cross-linking experiments (16) suggest the possibility of membrane-
bound hexokinase tetramers.  
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Results here are consistent with a Glu-6-P-induced conformational change in the N-terminal 
half of HKI that releases the enzyme from the membrane. Conceivably, the membrane-bound 
N-terminal domain is in its open conformation. The binding of Glu-6-P drives a 
conformational change of the N-terminal half to its closed state with an apparent dissociation 
constant of 35 µM. The conformational change in the N-terminal half disrupts critical 
interactions with the membrane mediated by Mg2+ and/or the N-terminal segment of HKI. 
This scenario requires Glu-6-P to bind to HKI in solution with higher affinity than to the 
membrane-associated enzyme. The Kd for the dissociation of Glu-6-P from HKI in solution 
(~1 µM, glucose present) is at least consistent with this requirement.  
Nucleoside triphosphates and pyrophosphate probably work by mechanisms distinct from 
that of Glu-6-P-mediated release. Crystallographic investigations have identified an adenine-
binding site near the N-terminal segment of HKI (14, 15). ATP-mediated release of HKI, 
observed by Rose and Warms (6), may involve nucleotide interactions at this site. The single 
binding site for Mg2+, critical for the binding of HKI to the membrane, may be connected 
with this adenine binding site or may be located elsewhere on the HKI molecule. The effects 
of adenine nucleotides and Mg2+ on HKI association/dissociation are potentially useful in 
mapping specific interactions between HKI and the mitochondrial membrane. 
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Abstract 
The suppression of apoptosis by mitochondrion-associated hexokinases I & II underscores 
the importance of understanding mechanisms of hexokinase release from the outer leaflet of 
the mitochondrion.  Glucose 6-phosphate releases brain hexokinase (HKI) from mitochondria 
by binding to the N-terminal half of the enzyme; however, the mechanism by which 
nucleotides release HKI is unknown.  Concentrations of ATP, ADP and AMP that affect the 
50% release of HKI from mitochondria are 11±2, 23.5±0.4, and 57±4 µM, respectively, 
indicating a slight dependence on the phosphoryl moiety.  Corresponding values for GDP and 
GMP (47±5 and 24±2 µM, respectively) indicate little or no discrimination between adenine 
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and guanine nucleotides.  Mutations designed to disrupt ligand association at three known 
adenine nucleotide binding sites of HKI have no significant effect on release properties.  
Mutations that decouple interactions between the N- and C-terminals halves of HKI slightly 
antagonize nucleotide release.  The data infer a mechanism of nucleotide release 
fundamentally different from that of glucose-6-phosphate.  Nucleotides bind either to a 
protein component of the mitochondrial membrane that displaces HKI or to a putative 
membrane-associated oligomer of hexokinase that differs from HKI in its properties of 
nucleotide association.  The voltage dependent anion channel (VDAC) is the likely target of 
nucleotide action in the former mechanism. 
 
Introduction 
Mammalian tissue contains four hexokinase isozymes (1-3), and of these, hexokinase 
I (HKI1) or brain hexokinase, has long been recognized as the “pacemaker of glycolysis” in 
brain tissue and the red blood cell (4).  The brain, which comprises less than 2% of human 
body weight utilizes at least one-quarter of the circulating blood glucose and approximately 
one-fifth of the oxygen consumed by the body (5).  Nevertheless, HKI is at least 95% 
inhibited under normal physiological conditions in brain tissue (4).  A number of ligands 
inhibit HKI; however, glucose 6-phosphate (Glu-6-P) is probably the primary physiological 
inhibitor of the type-I enzyme (6).  On the other hand, inorganic orthophosphate (Pi) is 
capable of ameliorating glucose-6-P inhibition under normal physiological conditions (7), 
although at elevated levels it inhibits of HKI by binding to the active site (8).  Hexokinase II 
(HKII) is functionally similar to HKI; however, Pi does not relieve Glu-6-P inhibition of the 
type-II isozyme (9). 
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HKI and HKII have evolved by the duplication and fusion of a primordial hexokinase 
gene similar to that of yeast hexokinase (10).  Each half of HKI and HKII exhibits significant 
sequence similarities (11).  For HKII both halves support catalysis and are each sensitive to 
inhibition by Glu-6-P (12), whereas only the C-terminal half of HKI supports activity (13).  
Nonetheless, both halves of HKI can bind Glu-6-P with high affinity, and moreover the 
binding of Glu-6-P to either half inhibits activity (14,15).  Pi binds with high affinity to the 
N-terminal half of HKI (16,17), and relieves Glu-6-P inhibition by an allosteric mechanism 
that couples both halves of the enzyme. 
HKI and HKII associate with the outer mitochondrial membrane in brain tissue (18), 
an interaction requiring fifteen, largely hydrophobic amino acid residues at its N-terminus 
(19).  HKI likely interacts with the voltage-dependent anion channel (VDAC) or porin of the 
outer mitochondrial membrane (20,21), and so positioned, has preferential access to newly 
formed mitochondrial ATP (18).  Evidently by binding to the mitochondrion, hexokinase I 
prevents the opening of the permeability transition pore (PTP) (22).  The PTP is a 
multicomponent system that includes the adenylate translocator (ANT) of the inner 
mitochondrion membrane, and the voltage dependent anion channel (VDAC) of the outer 
mitochondrion membrane (20,21,23-26), and is regulated by cyclophilin D of the inner 
mitochondrion matrix and the binding of hexokinase I & II (27-29). Opening of the PTP 
results in loss of membrane potential, organelle swelling, cytosolic acidification, and the 
release of cytochrome c (22,27).  Cytochrome c that escapes the mitochondrion after the PTP 
opens, activates the caspase family of proteases, which ultimately results in apoptosis (29-
31).  Others maintain that the opening of the PTP is a prelude to necrosis, not apoptosis, and 
that a pro-apoptotic protein such as Bax, triggers the release of cytochrome c without 
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mitochondrial swelling (27,32,33).  Nevertheless, mitochondrion-associated hexokinase II 
clearly antagonizes the action of pro-apoptotic factors such as Bax (34-36).  Pro-apoptotic 
proteins (Bax, Bak, and Bim) interact with VDAC in the assembly of large pores that 
presumably serve as conduits for the release of cytochrome c (32,33,37).  Indeed, over-
expression of VDAC-1 causes apoptotic cell death (38,39).  Hexokinase I&II, through their 
own associations with VDAC, may antagonize the formation of apoptotic channels.  Some 
have gone so far as to label hexokinase as “guardian of the mitochondria” (40).  Evidence so 
far is at least consistent with the hexokinase-bound mitochondrion acting as a checkpoint in 
apoptosis. 
A number of small and physiological important ligands are capable of dissociating 
HKI from the mitochondrial outer membrane.  These compounds include Glu-6-P and ATP 
(18).  Skaff et al. (41) demonstrated a wild-type recombinant HKI with properties 
comparable to native brain hexokinase including those of mitochondrial-binding and release.  
Their recombinant construct has an intact membrane targeting element and a formyl group 
attached to the amino terminus of the polypeptide chain.  The release properties of mutant 
constructs demonstrated the significance of Glu-6-P binding to the N-terminal half of HKI in 
promoting the release of the mitochondrion-associated enzyme.  The Glu-6-P release 
phenomenon adheres to a simple equilibrium model. 
To date, little is known regarding the mechanism of ATP-induced release of HKI 
from mitochondria (18).  Three binding sites exist on HKI for adenine nucleotides: the active 
site at the C-terminal half (13), the Pi binding site at the N-terminal half at which the 
nucleotide may bind through its terminal phosphoryl group (42), and the nucleotide pocket of 
unknown function near the N-terminal membrane targeting element (42,43).  The purpose of 
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the present study was to investigate the release of HKI by purine nucleotides, and which, if 
any, of the adenine nucleotide binding sites of HKI are responsible for that release.  Purine 
nucleotides at concentrations below 100 µM are in general effective agents in the release of 
HKI from mitochondria; however, none of the known purine nucleotide binding sites 
associated with HKI are responsible for the release phenomenon.  A high-affinity binding site 
for purine nucleotides exists, but it targets a protein in the outer leaflet of the mitochondrion, 
causing a conformational change that disrupts HKI association, or targets a binding site 
which destabilizes an aggregated form of HKI, necessary for mitochondrion recognition. 
 
Materials and Methods 
Materials—ATP, NADP, Glu-6-P, chloramphenicol, deoxyribonuclease (DNase I), leupeptin 
and phenylmethylsulfonyl fluoride came from Sigma.  Kanamycin sulfate was purchased 
from Invitrogen.  DEAE HPLC resin was a product of Tosohaas.  Nickel-nitrilotriacetic acid-
agarose (NiNTA) resin and Rosetta (DE3) competent cells were from Novagen.  Glucose-6-
phosphate dehydrogenase was obtained from Roche Molecular Biochemicals.  Isopropyl-1-
thio-β-D-galactopyranoside (IPTG) came from Anatrace.  The HKI inhibitor 1,5-
anhydroglucitol 6-phosphate (AnGlu-6-P) was prepared as described elsewhere (15). 
Construction of Wild-type Hexokinase and Mutant Plasmids—Human brain hexokinase 
(HKI) had been cloned into pET-24b with a 10-residue histidine tag at its C-terminus as 
reported in a previous study (41).  Hexokinase mutants were created through PCR 
modification with oligonucleotide primers synthesized at the Iowa State University DNA 
Sequencing and Synthesis Facility.  The production of the mutant hexokinase plasmids for 
Thr232→Ala, α+2, Thr232→Ala/α+2 are described elsewhere (41).  The N-terminal half 
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nucleotide binding site mutant, Asn384→Arg, was created with the following forward primer 
(and its reverse compliment): 5’-CACCATTGTCTCATTTCGCTCAGCCCGCTTGGTGGC 
TGCCACACTGGGCGCC-3’ (modified nucleotides are underlined).  The combination 
mutant Asn384→Arg/Thr232→Ala/α+2 employed the above primers and the Thr232→Ala/α+2 
plasmid.  Sequences for all HKI mutants were verified at the Iowa State University DNA 
Sequencing and Synthesis Facility. 
Expression and Purification of Wild-Type and Mutant Hexokinases—Wild-type or mutant 
pET-24b-HKI plasmids were transformed into Rosetta (DE3) cells.  Expression and 
purification HKI enzymes are discussed in detail by Skaff et al (41).  Protein concentrations 
employed the Bradford method with bovine serum albumin as a standard (44). 
Pig Liver Mitochondria Purification—Pig livers were obtained from the Iowa State 
University Meats Laboratory shortly after slaughter.  Mitochondrial purification is described 
(45) with modifications as discussed elsewhere (41).  Mitochondria were stored at –80º C in 
the presence of 5% dimethyl sulfoxide. 
The HKI Activity Assay—Hexokinase activity was measured using the glucose 6-phosphate 
dehydrogenase-coupled spectrophotometric assay at pH 8.0 (46).  The coupled assay 
circumvents the influence of potent product inhibition, but complicates the determination of 
inhibition constants for Glu-6-P.  “Glu-6-P inhibition” is measured by the effect of a 
surrogate inhibitor AnGlu-6-P, which is neither a substrate nor inhibitor of glucose 6-
phosphate dehydrogenase.  Initial rate data were analyzed using the GraFit computer 
program (47).  For kinetic measurements of HKI on the mitochondrial membrane, whole 
mitochondria with bound hexokinase were added to the assay and velocities were measured 
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using the spectrophotometer.  These data were analyzed by nonlinear least squares fits (using 
GraFit) to models described in the Results section. 
Circular Dichroism Spectra—Circular dichroism spectra were measured using a Jasco J710 
circular dichroism spectrometer.  The data were collected at room temperature between 200 
and 260 nm.  The concentration of HKI used in these measurements was 0.2 mg/mL in 2 mM 
HEPES (pH 7.8) with 0.2 mM glucose and 2 mM β-mercaptoethanol. 
Mitochondrial Binding and Release— Prior to carrying out the binding experiments, HPLC-
purified HKI was passed over a Sephadex-G50 column (Sigma) for desalting and to equilibrate the 
enzyme solution with the mitochondrial-binding buffer, and then diluted to 2 mg/mL.  The 
mitochondrial binding buffer contains 250 mM sucrose, 5 mM Glc, 20 mM NaCl, 5 mM MgCl2 and 5 
mM HEPES, pH 7.4.  Mitochondria were diluted into this buffer to a concentration of 3 mg/mL, wet 
weight.  Purified HKI and mitochondria were mixed and allowed to stand for 90 minutes on ice, and 
then centrifuged at 10,000 × g for 8 minutes.  Unbound HKI in the supernatant fluid was decanted.  
Pelleted mitochondria were resuspended in mitochondrial-binding buffer, less the MgCl2 and Glc, and 
re-centrifuged.  This wash step was repeated, after which pelleted mitochondria were resuspended in 
the mitochondrial-binding buffer (MgCl2 and Glc absent) and assayed for HKI activity (MgCl2 
included with ATP). 
HKI release from the mitochondria was performed as follows: HKI was bound to 
mitochondria as above, and then resuspended in a release buffer containing 250 mM sucrose and 5 
mM HEPES, pH 7.4.  100 µL aliquots of this solution were distributed to plastic micro-centrifuge 
tubes, to which was added ATP (or another nucleotide) at various concentrations and allowed to sit 
for 30 minutes at room temperature.  The mitochondria were pelleted by centrifugation.  HKI 
solubilized by nucleotide was removed by decanting the supernatant liquid.  The mitochondrial pellet 
was resuspended in 250 mM sucrose and 5 mM HEPES, pH 7.4, and centrifuged again.  After 
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discarding the supernatant fluid, pelleted mitochondria were resuspended, and then assayed for 
hexokinase activity. 
Results 
Rationale for the Selection of Mutants— In a crystal structure of an adenine nucleotide 
complex of an engineered monomer of HKI, ADP binds to as many as three sites: the active 
site of the C-terminal half, the site for Pi and the 6-phosphoryl group of Glu-6-P at the N-
terminal half, and a site near the membrane targeting element of the N-terminal half (42).  
Weak electron density covers the entire ADP molecule at the C-terminal half, strong electron 
density appears only at phosphoryl site for Pi/Glu-6-P of the N-terminal half, inferring at 
most the ordered binding of a terminal phosphoryl group, and strong electron density for an 
entire ADP molecule at the site near the membrane targeting element.  The mutation of 
Thr232→Ala eliminates Pi-relief of AnGlu-6-P inhibition in full-length HKI (14), and should 
eliminate the possibility of an adenine nucleotide interaction at the Pi/Glu-6-P site of the N-
terminal half.  Similarly the mutation of Thr536 to alanine (a residue that interacts with the 6-
phosphoryl group of Glu-6-P and the phosphoryl moiety of ADP (15,42)) should diminish 
the binding of adenine nucleotides to the C-terminal half of HKI.  Finally, the mutation 
Asn384→Arg removes a hydrogen bond between atom OD1 of Asn384 and the N-6 atom of 
the adenine nucleotide (42), while filling a portion of the adenine binding pocket with a 
larger side chain.  The hydroxyl group of Thr376 is located near the N-3 atom of the bound 
adenine nucleotide; the mutation Thr376→Tyr should fill space occupied by the bound 
nucleotide required without the introduction of poor non-bonded contacts between atoms of 
the protein.  The Asn384→Arg and Thr376→Tyr mutations should test whether adenine 
nucleotide site near the membrane targeting element is responsible for the release of HKI 
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from the mitochondrion.  The α+2 mutation (41) separates the two halves of HKI by the 
addition of two full turns of the transition helix.  Binding of Glu-6-P to either half of HKI 
causes complete inhibition of the enzyme, requiring an inhibitory mechanism which couples 
the two halves of the enzyme (14,15).  The α+2 construct eliminates the functional coupling, 
by increasing the separation of the two halves of HKI by approximately 11 Å, while leaving 
the N- and C-terminal halves in approximately the same relative orientation..  Finally, 
Thr232→Ala and Thr232→Ala/α+2 constructs raise the I0.5 value for Glu-6-P-release of HKI 
from them mitochondria more than 7-fold (41), and will determine whether the release 
mechanism cause by nucleotides is related to that caused by Glu-6-P.   
Kinetic Analysis of Wild-type and Mutant Enzymes— Kinetic parameters of wild-type and mutant 
constructs are shown in Table ONE.  AnGlu-6-P, which mimics the inhibition of Glu-6-P (See 
Experimental section), is a competitive inhibitor with respect to ATP and noncompetitive inhibitor 
with respect to glucose (48). 
ATP-induced Release of Wild-type and Mutant Hexokinases from Mitochondria— Incubation 
times of twenty and sixty minutes produced nearly identical release curves (Figure ONE), 
indicating an equilibrium phenomenon.  Scheme I represents the simplest equilibrium model 
that accounts for ATP-release of wild-type and mutant enzymes from mitochondria. 
E + 1M = E1M,  K1 = [E1M]/[E][1M] 
E1M + I = E1MI  K1i = [E1MI]/[E1M][I] 
1M + I = 1MI  Ki = [1MI]/[1M][I] 
    Scheme I 
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Table ONE 
Kinetic parameters for wild-type and mutant HKI constructs.  Assays as described in the 
experimental section.  Determination of kcat employed concentrations of Glc and ATP of 1.6 
mM and 9 mM.  Determination of KmATP employed a Glc concentration of 1.6 µM and 
concentrations of ATP of 0.3–7.5 mM.  Determination of KmGlc employed an ATP 
concentration of 9 mM and concentrations of Glc of 10–600 µM  Determination of KiAnGlu-6-P 
employed Glc concentration of 1.6 µM, concentrations of ATP of 0.75–4.5 mM, and 
concentration of AnGlu-6-P of 0–100 µM. 
 
 
Enzyme kcat KmATP KmGlc KiAnGlu-6-P 
 sec-1 mM µM µM 
Wild-type, His-tagged 93±3 1.3±0.4 76± 5 38±4 
Thr232→Alaa,b 70±2 0.81±0.04 42±2 84±5 
α+2b 47±1 1.9±0.1 48±3 28±1 
α+2/Thr232→Alab 56±1 1.8±0.1 180±10 22±1 
Thr376→Tyr 69±4 1.6±0.2 141±11 42±5 
Asn384→Arg 92±2 2.8±0.2 157±11 58±5 
 
Table ONE.  Footnotes. 
aFrom reference (14). 
bWithout a C-terminal polyhistidyl tag. 
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Figure ONE  Time dependence of ATP-induced release of HKI from mitochondria.  
Mitochondria laden with HKI in 250 mM sucrose and 5 mM HEPES, pH 7.4, were allowed to 
incubate with increasing concentrations of ATP for 20 minutes (■) and 60 minutes (♦).  
Plotted here are relative velocities of HKI remaining on the mitochondrion versus 
concentration of ATP.  Equal concentrations of MgCl2 were added with ATP.  Solid lines 
represent fitted curves generated from Equation 3.   
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In Scheme I, K1, K1i and Ki represent association constants.  A uniform class of 
mitochondrial binding sites is represented by 1M, E is the wild-type or mutant HKI and I is 
ATP (or other nucleotide).  The mathematical relationship derived from the model of Scheme 
I also represents the more complex situation of n different types of mitochondrial binding 
sites, 1M, 2M, 3M,…nM, as discussed by Skaff, et al. (41).  Moreover, the simple model 
represented in Scheme I attributes the release of HKI to the binding of one molecule of ATP 
to a site on the mitochondrion rather that to site on HKI.  (Results will support this aspect of 
the model).  In fact, the mathematical model the results from Scheme I is identical to that 
from previous work, based on the binding of effector with HKI.  Hence, data for the wild-
type enzyme alone can not distinguish between effector binding to a site on HKI or the 
mitochondrion. 
Using the equations in Scheme I, the fraction of the total mitochondrial binding sites 
occupied by HKI (S) as a function of [I] is: 
S([I]) = {K1[E] + K1[E]K1i[I]}/{1 + K1[E] + K1[E]K1i[I] + Ki[I]}             (1) 
The velocity of the bound enzyme is proportional to the fraction of HKI-occupied 
mitochondrial sites, therefore, the observed velocity is related to [I] as: 
V([I]) = aS([I])         (2) 
where a is the constant of proportionality.  By making substitutions, Equation 2 becomes: 
V([I]) = a{(b+c[I])}/(1+b+c[I]+Ki[I])}      (3) 
where b = K1[E]  and c = K1[E]K1i.  In the absence of ATP, mitochondrial sites are saturated 
with HKI.  Therefore, b must be large relative to unity so that at I = 0, V(0) = a{b/(b+1)} = 
~a. 
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To facilitate the comparison of release data, we define I0.5 as the concentration of 
ATP at which one-half of the mitochondrial sites are occupied by HKI and V0.5 as the 
corresponding velocity.  V0.5 is the midpoint of V([I] = 0) and V([I] = ∞): 
V0.5 = (a/2){[b/(b+1)] + [c/(c+Ki)]}       (4) 
I0.5 comes from Equation 3 using V0.5 from Equation 4: 
I0.5 = [V0.5 – b(a – V0.5)]/[c(a – V0.5) – KiV0.5]      (5) 
Equation 2 was used to fit wild-type and mutant hexokinase constructs using non-linear least 
squares.  Correlations between Ki, b, and c make refinement of the three parameters difficult.  
However, titration of ATP into mitochondria saturated with wild-type hexokinase resulted in 
parameters with associated uncertainties of 10% or less.  The Ki value for mutant HKI constructs 
were fixed to the wild-type value of 9.5 µM and the allowing a, b, and c to refine to their 
optimal values.  We found that fixed values for Ki ranging from 0.5 to 100,000 µM caused 
significant changes in the refined values of a, b, and c; however, I0.5, V0.5 and percent limiting 
release values remained within their estimated variances.  Hence as in previous work, I0.5 and 
limiting release serve well in the comparison of release phenomenon. 
 Multiple runs of ATP release of wild-type HKI from mitochondria (Figure TWO) yield 
I0.5 and limiting release values that vary by less than 5% (Table TWO).  Average values for I0.5 
limiting release of wild-type HKI by ATP are 11.0±0.5 µM and 96.7±0.7 % for I0.5 and 
limiting release, respectively.  All mutations of HKI have no more than a three-fold effect on 
I0.5, but more substantial effects on limiting release.  The mutation Thr232→Ala marginally 
increases the I0.5 value but limiting release is 25% lower than for the wild-type enzyme.  The 
two mutations in the nucleotide binding site near the membrane targeting element of the N-
terminal half have opposite and modest effects on I0.5, and exhibit lower values for limiting 
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release relative to the wild-type enzyme.  The α+2 and α+2/Thr232→Ala constructs have I0.5 
values modestly higher than that of the wild-type enzyme and significantly lower values of 
limiting release.  The effect of the Thr232→Ala mutation on the wild-type enzyme and the 
α+2 construct is a similar 25% decrease in the limiting release. 
Nucleotide Specificity in HKI Release from Mitochondria—The model based on Scheme I 
was used in the analysis of data for the release of wild-type HKI from the mitochondrion by 
ADP, AMP, GDP and GMP (Table THREE).  Removing phosphoryl groups from ATP 
increases I0.5 only two- and four-fold for ADP and AMP, respectively (Figure THREE).  GDP 
and GMP released HKI from the membrane essentially as effectively as adenine nucleotides.  
Limiting release values for all purine nucleotides were essentially the same. 
Rose and Warms (18) demonstrated the release of HKI from mitochondria by ATP and other 
nucleotides at millimolar concentrations.  The importance of the hexokinase-mitochondrion 
interaction to apoptosis motivated our efforts to quantify and better define the mechanism of 
nucleotide release of HKI from mitochondria. 
The experimental protocols adopted here avoid the combination glucose and ATP, which in 
the presence of HKI would result in the generation of copious amounts of Glu-6-P.  Internal 
controls demonstrate the absence of significant concentrations of Glu-6-P in our ATP release 
experiments.  For instance, we observe little difference between our AMP, ADP 
and ATP release data, as would be expected if no Glu-6-P were generated under 
conditions employed in gathering ATP-release data.  Furthermore, the Thr232→Ala and 
Thr232→Ala/α+2 constructs have indistinguishable I0.5 values relative to each other and to the 
wild-type and α+2 enzymes (Table TWO), which would not be the case if release were due to  
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Figure TWO  ATP-induced release of HKI from pig liver mitochondria.  Mitochondria with HKI 
bound were suspended in 250 mM sucrose and 5 mM HEPES, pH 7.4, after exposure to 
varying concentrations of ATP containing an equal ratio of MgCl2.  The plots represent 
relative velocities from mitochondrion-bound HKI that remains after a 45-minute incubation 
with ATP.  Equation 3 and the parameters in Table TWO were used to produce the fitted 
curves shown as solid lines.  The HKI constructs are as follows wild-type (■), the 
Thr232→Ala mutant enzyme (♦), the α+2 construct (◊), the Thr376→Tyr mutant enzyme (▲), 
Asn384→Arg mutant enzyme (□) and the α+2/Thr232→Ala mutant enzyme (∆).   
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Table TWO 
Fitted parameters for ATP-induced release of mitochondrial HKI.  Parameters a, b, c, Ki, and 
I0.5 are defined in the Results section.  Standard deviations in the last significant digit are 
given in parentheses. 
HKI construct a b c K I0.5a 
Relative 
velocity 
at I0.5b 
Limiting 
release 
 µM s-1  µM–1 µM µM  %c 
Wild-type 0.01193(9) 107(3) 0.33(8) 9.5(3) 11.0(5) 0.512(7) 96.7(7) 
Thr232→Ala 0.1486(7) 160(40) 3.6(7) 9.5 12(5) 0.63(4) 73(4) 
Thr536→Ala 0.00140(9) 400(200) 4.0(1.6) 9.5 33(20) 0.65(7) 71(9) 
Thr376→Tyr 0.0070(1) 75(4) 1.7(2) 9.5 6.8(6) 0.57(1) 85(1) 
Asn384→Arg 0.064(1) 500(100) 5.0(8) 9.5 35(3) 0.67(3) 66(3) 
α+2 0.0339(8) 410(90) 7.7(9) 9.5 24(7) 0.72(3) 55(3) 
α+2/Thr232→Ala 0.10236(4) 1300(100) 24(1) 9.5 40(5) 0.858(7) 28.4(9) 
 
Table TWO.  Footnotes. 
aKi is an optimized parameter for the wild-type enzyme and then fixed at this value for all mutants. 
bCalculated using Equation 5. 
cV0.5/a, where V0.5 is calculated from Equation 4. 
dPercent limiting release = 100x(1–V∞/a), where V∞=c/(c+Ki). 
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Table THREE 
 Fitted parameters for nucleoside-induced release of mitochondrial HKI.  Parameters a, b, c, 
Ki, and I0.5 are defined in the Results section.  Standard deviations in the last significant digit 
are given in parentheses. 
Nucleoside a b c Ka I0.5b 
Relative 
velocity at 
I0.5c 
Limiting 
release 
 µM s-1  µM–1 µM µM  %d 
ATP 0.0194(7) 110(10) 0.1(2) 9.5 11(2) 0.50(3) 99(2) 
ADP 0.01537(5) 229(2) 0.28(2) 9.5 23.5(4) 0.512(3) 97.1(2) 
AMP 0.0124(2) 560(30) 0.3 (1) 9.5 57(4) 0.51(1) 97(1) 
GDP 0.0108(2) 410(30) 0.3(2) 9.5 42(5) 0.51(2) 97(2) 
GMP 0.01329(3) 250(2) 0.84(2) 9.5 24.2(2) 0.539(2) 91.8(1) 
 
Table THREE.  Footnotes. 
aKi is an optimized parameter for the wild-type enzyme from Table TWO. 
bCalculated using Equation 5. 
cV0.5/a, where V0.5 is calculated from Equation 4. 
dPercent limiting release = 100x(1–V∞/a), where V∞=c/(c+Ki). 
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Figure THREE  Nucleotide-induced release of HKI from mitochondria.  HKI-bound mitochondria 
in 250 mM sucrose and 5 mM HEPES, pH 7.4, were incubated with varying concentrations 
of ATP (■), ADP (♦) and AMP (▲).  Relative velocities of HKI remaining on the 
mitochondrion are plotted versus increasing concentrations of nucleotide.  All nucleotides 
contained an equal molar ratio of MgCl2.  The solid lines are generated from the parameters 
in Table TWO and Equation 3.   
 
 
the formation of Glu-6-P from ATP and contaminating levels of Glc.  Hence, the effects 
observed here are due to the nucleotide. 
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Discussion 
Mutations that interrupt the known binding sites for ADP in HKI have no effect on 
I0.5 values (Table TWO).  Unlike Glu-6-P, which releases HKI by direct interaction with its 
binding site at the N-terminal half, the release of HKI by ATP does not involve any of the 
known adenine nucleotide binding sites of HKI.  The results infer three mechanisms of ATP 
release: ATP binds at a site that exists only in a membrane-associated multimer of 
hexokinase, ATP binds to a membrane protein causing a conformational change that 
displaces HKI, or ATP binds to membrane protein blocking a site recognized by HKI. 
The first mechanism attributes release to adenine nucleotide binding sites that exist 
only in a multimer of HKI.  But do HKI multimers exist?  At the highest concentrations of 
HKI in solution, the enzyme crystallizes as a dimer in the presence of Glc and Glu-6-P 
(49,50) in the presence of Glc and Pi (17), and in the presences of ATP, Glu-6-P, and Glc 
(42,43).  The latter complex reveals no adenine nucleotide of the dimer not observed in the 
ADP complex of an engineered hexokinase monomer (42).  If a multimer of HKI beyond the 
dimer is present in solution, then it has yet to be crystallized.  Cross-linking studies of Wilson 
and Xie (51) support the existence of soluble and mitochondrion-bound HKI tetramers.  
These investigators (as do we) observe non-cooperative binding of HKI to mitochondria.  
Hence, HKI cannot initially bind to mitochondria as a monomer, and then assemble into a 
tetramer; however, if solution pools of monomeric and tetrameric hexokinase are in slow-
exchange, then pre-formed solution tetramers can load onto mitochondria without 
cooperativity.  No data in the literature suggests the binding of ATP to the HKI tetramer 
differs from that of the monomer or dimer.  Indeed, a photo-affinity analog of the adenine 
nucleotide labels HKI in solution at the N-terminal domain within the first 100 residues and 
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at the C-terminal domain (52)??, corresponding respectively to adenine nucleotide sites near 
the membrane targeting element and the active site, confirmed subsequently by 
crystallographic studies. 
The latter two mechanisms are variations of ligand competition in which the binding 
of ATP and HKI to a membrane protein are mutually exclusive.  The most likely candidate 
for this membrane protein is the VDAC.  An adenine photo-affinity label defines three 
potential binding sites on VDAC for the adenine nucleotide (53).  One site may be on the 
cytosolic face of the VDAC (53), and perhaps directly involved in the recognition of HKI.  
The cytosolic adenine nucleotide binding site in proposed models of VDAC is not far from 
Glu72 and Thr51.  Modification of Glu72 of VDAC by dicyclohexylcarbodiimide blocks the 
binding of HKI to the mitochondrion (54-56).  Moreover, Glu72→Gln VDAC causes a 70% 
reduction in mitochondrion-associated HKI (38), and phosphorylation of VDAC by glycogen 
synthase kinase 3β at Thr51 blocks the association of HKII with the mitochondrion (57). 
If the same release mechanism works for AMP, ADP, ATP, GMP, and GDP, then the 
release site probably recognizes the nucleotide primarily through its 5′-phosphoribosyl 
moiety.  Little variation in I0.5 is evident due to differences in base moiety or the number of 
phosphoryl groups of the nucleotide.  Mitochondria harvested from brain tissue have bound 
HKI (58).  Given prevailing concentrations of Glu-6-P and adenine nucleotides in vivo, other 
ligands must antagonize the effects of Glu-6-P and nucleotides.  Pi specifically antagonizes 
Glu-6-P release of HKI (18), and Mg2+ is a likely antagonist of all effectors that release HKI 
from the mitochondrion.  We cannot exclude the possibility here that the nucleotide release 
site recognizes a phospho-sugar that stabilizes the membrane-bound state of HKI, and that 
the base moiety of the nucleotide sterically blocks the association of HKI. 
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The mechanism of ATP release of mitochondrion-bound HKI differs in yet another 
way from that of Glu-6-P release.  The percent limiting release of HKI due to Glu-6-P 
increases approximately 30% due the decoupling of the N- and C-terminal halves of the 
enzyme (see data for the α+2 and Thr232→Ala/ α+2 constructs in Skaff et al. (41)).  In 
contrast, the percent limiting release of HKI due to ATP decreases from 97% to 55% and 
30% for the α+2 and Thr232→Ala/ α+2 constructs, respectively.  These data infer that 
coupling interactions between the N- and C-terminal halves of HKI modestly impede the 
mechanism of Glu-6-P release of HKI, whereas that same interactions support ATP release of 
HKI.  Figure FOUR illustrates how conformational states of a HKI monomer can account for 
differences in the extent of release.  We assume two conformational states for the N-terminal 
half of HKI, a closed conformation in the presence of Glu-6-P and an opened conformation 
in its absence.  The membrane-bound state favors the opened N-terminal half, and coupling 
interactions from the C-terminal half stabilize the opened N-terminal half.  Glu-6-P releases 
HKI with a close N-terminal half and a non-coupled C-terminal half.  In contrast, the binding 
of ATP binding to the VDAC does not stabilize HKI with a closed N-terminal half.  Hence, 
HKI releases from the mitochondion with an opened N-terminal half and strong coupling 
interactions with its C-terminal half.  Differences in limiting release in this model arise from 
differences in the conformational states of HKI (presence or absence of bound Glu-6-P) and 
the VDAC (presence or absence of bound nucleotide).  In reality, the situation is potentially 
far more complex than that depicted in Figure FOUR.  HKI may be present as an oligomer as 
well as a monomer and VDAC is present in at least three different isoforms (59) that may 
differ further by levels of phosphorylation (57). 
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If indeed, the HKI-mitochondrion complex is a checkpoint in apoptosis and/or 
necrosis, then it represents a significant target in cancer therapy.  In some cancers, apoptosis 
may be blocked by conditions that stabilize HKI and HKII on the mitochondrion (27).  In 
principle, an effector that unconditionally releases hexokinase from the mitochondria, would 
allow apoptosis to go forward in compromised cells, but cause few negative consequences 
for healthy cells. 
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Figure FOUR  Proposed model of release of HKI from the mitochondrial membrane.  HKI is 
shown with the N-terminus in the open formation.  Binding of glucose 6-phosphate to HKI 
causes a conformational change that closes the N-half and causing the release of HKI from 
the membrane.  In the second case, ATP binding to the VDAC causes the release of HKI 
from the membrane without conformational change in HKI.   
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Abstract 
The nucleotide binding pocket near the N-terminus of human brain hexokinase has been 
proposed to function as either the source of nucleotide-induced release of HKI from the 
mitochondrial membrane or as the locus of allosteric inhibition of the protein.  It has been 
recently determined that the nucleotide appears to bind to porin or another portion of the 
permeability transition pore and not HKI.  ADP has been shown to be a noncompetitive 
inhibitor relative to ATP leading to the proposal of an allosteric binding site. X-ray 
diffraction crystallography of HKI identified a nucleotide binding site near the N-terminus.  
The allosteric site responsible for causing the noncompetitive inhibition has ever been 
identified.  Using site-directed mutagenesis, constructs of HKI that preclude binding to ADP 
to the N-terminal site and other potential nucleotide binding pockets were created.  The 
nucleotide binding site near the N-terminus is indeed responsible for allosteric inhibition of 
HKI.  Synergism was not detected between nucleotide and glucose 6-phosphate inhibition.   
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Introduction 
The human brain comprises less than 2% of the body mass but utilizes more than one-
quarter of the blood glucose (1).  Mammalian tissues contain four isozymes of hexokinase 
(ATP:D-hexose 6-phospho-transferase (2.7.1.1.)), however, the brain contains primarily a 
single form known as Type I hexokinase (HKI) (2-4).  Although HKI is more than 95% 
inhibited under physiological conditions, it has been long recognized to be the “pacemaker of 
glycolysis” (5).    Increased hexokinase activity has been detected in immortal cancer cells 
along with higher expression (6,7).  Recent studies have tied hexokinase association with 
porin and the permeability transition pore on the mitochondrial membrane to the prevention 
of apoptosis (8-10).   Glucose 6-phosphate (Glu-6-P) and nucleotides have been shown to 
dissociate HKI from the mitochondrial membrane (11).  Removal of HKI from the membrane 
may signal for its degradation (11) and/or one of the initial steps of apoptosis (6,10,12). 
 X-ray diffraction crystallography studies have shown the HKI monomer to be 
comprised of two similar lobes (13-16).  The C-terminal half contains the active site while 
the N-terminal half has been shown to have regulatory properties including orthophosphate 
relief of Glu-6-P inhibition (17) and release of HKI from the mitochondria due to binding of 
Glu-6-P (18).  Glucose and Glu-6-P/Pi will bind to a site analogous to the active site in the 
N-half.  An additional nucleotide binding site was found near the N-terminal mitochondrial 
binding helix, far removed from the analogous active site (15).  While no function has been 
assigned to the nucleotide binding site, it has been hypothesized that 1) nucleotide induced 
release from mitochondria and/or 2) ADP inhibition is directed through this site (19).  A 
recent study has shown that nucleotide binding, associated with HKI release from 
mitochondria, is a result of nucleotide binding to the mitochondrion rather than to HKI 
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(unpubished).  The goal of the present study was to determine the function of the N-terminal 
half nucleotide binding site in ADP inhibition.  Ning, et al, first observed noncompetitive 
inhibition of ADP versus ATP and proposed that there is an allosteric site removed from the 
active site (19).  While the nucleotide binding site near the N-terminus is a likely source of 
inhibition, we also considered the possibility that nucleotides were binding to the Glu-6-P/Pi 
binding locus.  It is conceivable that the phosphoryl moiety of the nucleotide is bound at this 
site with the nucleotide base extended into solution.  Through a series of mutations we have 
determined that the N-terminal half nucleotide binding site is responsible for the 
noncompetitive inhibition observed in earlier studies.   
Materials and Methods 
Materials—ATP, ADP, NADP, chloramphenicol, deoxyribonuclease (DNase I), leupeptin 
and phenylmethylsulfonyl fluoride came from Sigma.  Kanamycin sulfate was purchased 
from Invitrogen.  Isopropyl-1-β-D-galactopyranoside came from Anatrace.  Nickel-
nitrilotriacetic acid-agarose (NiNTA) resin and Rosetta (DE3) competent cells were from 
Novagen.  DEAE HPLC resin was a product of Tosohaas.  Glucose 6-phosphate 
dehydrogenase was obtained from Roche Molecular Biochemicals.  The HKI inhibitor, 1,5-
anhydroglucitol 6-phosphate (AnGlu-6-P), was available from a previous study (20).   
Construction of wild-type Hexokinase and mutant plasmids—Full-length human brain 
hexokinase had been cloned into pET-24b with a 10X histidine tail in a previous study (18).  
Hexokinase mutants were created through PCR modification with oligonucleotide primers 
synthesized at the Iowa State University DNA Sequencing and Synthesis Facility.  The 
production of the mutant hexokinase plasmids for Thr232→Ala, α+2, Thr232→Ala/α+2 and 
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Asn384→Arg are described elsewhere (18).   All HKI mutants were sequence verified at the 
Iowa State University DNA Sequencing and Synthesis Facility.   
Expression and Purification of Wild-Type and Mutant Hexokinases—Wild-type or mutant 
pET-24b-HKI plasmids were transformed into Rosetta (DE3) cells.  Expression and 
purification are discussed in detail in Skaff et al (18).  Protein concentrations were measured 
using the Bradford method with bovine serum albumin as the standard (21).   
The HKI Activity Assay—Hexokinase activity was measured using the glucose 6-phosphate 
dehydrogenase-coupled spectrophotometric assay at pH 8.0 (22).  Initial rate data were 
analyzed using the GraFit computer program (23).  Determinations between models of 
inhibition were made using Dynafit (24).   
Circular Dichroism Spectra—Circular dichroism spectra were measured using a Jasco J710 
circular dichroism spectrometer.  The data were collected at room temperature between 200 
and 260 nm.  The concentration of HKI used in these measurements was 0.2 mg/mL in 2 mM 
HEPES (pH 7.8) with 0.2 mM glucose and 2 mM β-mercaptoethanol.   
Results 
Rationale for the Selection of Mutants— The α+2 mutation adds two full turns of the 
transition helix and effectively separates the two halves of HKI in a functional sense.  Glu-6-
P binding to either half of HKI has been shown to influence the conformation of the opposite 
half (20,25).  This coupling mechanism between HKI halves is severely hampered without 
altering the relative orientation with the α+2 construct.   The Thr232→Ala mutation eliminates 
Pi-relief of AnGlu-6-P inhibition in full-length HKI (25).  The mutation of Asn384→Arg 
removes a hydrogen bond between the side chain oxygen of asparagine 384 and the N-6 
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position of ATP and fills a portion of the nucleotide binding site with a larger amino acid 
which should impair ATP binding to this location.     
Kinetic Analysis of Wild-type and Mutant Enzymes—Kinetic parameters of the wild-type and 
mutant HKI constructs are shown in Table ONE.  AnGlu-6-P, which mimics the inhibition of 
Glu-6-P but is not a substrate for the coupled assay (26), is a competitive inhibitor with 
respect to ATP and noncompetitive inhibitor with respect to glucose.   
Relief of Inhibition by Inorganic Phosphate—Inorganic phosphate has been shown to relieve 
inhibition caused by AnGlu-6-P (27,28).  Shown in Panel A of Figure ONE is one such 
experiment.  Panel B shows the same experiment substituting ADP inhibition for AnGlu-6-P.  
The result shows that phosphate has no effect on ADP inhibition indicating that the Glu-6-
P/Pi binding site in the N-half is not the location of the allosteric binding site.  This result will 
be verified in the mutational analysis.   
ADP Inhibition of Wild-type and Mutant Hexokinase—ADP inhibition of wild-type HKI was 
found to be noncompetitive in terms of ATP (19).  Models for noncompetitive inhibition use 
the following equilibria to produce equation 1.   
E + S = ES    Km 
E + I = EI      Ki 
ES + I = ESI    Kii 
 



 +++=
SK
IK
K
I
S
K
Vv i
m
ii
m
m
111
    Eq. 1  
It is expected that if the allosteric site of HKI were to be eliminated, the Kii equilibrium term 
in the equilibria would be unnecessary and the model for competitive inhibition would 
provide a better fit for data.  Equation 1 would then collapse to form Equation 2.   
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Table ONE. 
Kinetic parameters for wild-type and mutant HKI constructs. 
 
Enzyme kcat KmATP KmGlc KiAnGlu-6-P 
 sec-1 mM µM µM 
Wild-type, His-tagged 93±3 1.3±0.4 76± 5 38±4 
Thr232→Alaa,b 70±2 0.81±0.04 42±2 84±5 
α+2b 47±1 1.9±0.1 48±3 28±1 
Asn384→Arg 92±2 2.8±0.2 157±11 58±5 
aFrom reference (25) 
bWithout His tag. 
 
 
 

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     Eq. 2 
Results of this analysis along with the best fit model are shown in Table TWO.  Data from 
this table were used to generate the solid lines in Figure TWO.  The wild-type enzyme with a 
histidine tag exhibited data that fit to the noncompetitive model as did non-histidine tagged 
HKI in previous studies (18).  Data analysis shows a Km for ATP of 2.6±0.3, Ki for ADP of 
2.2±0.4 and Kii of 6±2.  The mutant α+2, which functionally separates the two halves of HKI, 
shows that the competitive inhibition model provides the best fit (Figure TWO, Panel B).   
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Figure ONE.  Inorganic phosphate relief of wild-type HKI.  Panel A –  Phosphate relief of 
AnGlu-6-P inhibition.  Glucose and ATP concentrations are held constant at 1.6 mM 
and 1.05 mM respectively.  Concentrations of AnGlu-6-P are varied from 0 to 250 
µM.  Potassium phosphate concentrations are 0 mM (■), 3 mM (♦) and 6 mM (▲).  
Plotted here is reciprocal velocity versus concentration of AnGlu-6-P.   
Panel B – ADP inhibition at varying concentrations of inorganic phosphate.  Glucose 
and ATP concentrations are held constant at 1.6 mM and 1.05 mM respectively.  
Concentrations of ADP are varied from 0 to 6 mM.  Potassium phosphate 
concentrations are 0 mM (■), 3 mM (♦) and 6 mM (▲).  Plotted here is reciprocal 
velocity versus ADP concentration.   
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This result confirms that the allosteric site for nucleotides is in the N-half of HKI.  Although 
inorganic phosphate showed no effect on ADP inhibition, the Thr232→Ala mutant was 
utilized to confirm this result.  ADP inhibition for this mutant was identical to that of the 
wild-type protein.  Finally, the nucleotide binding site mutant Asn384→Arg was tested for 
ADP inhibition versus ATP.  As with the α+2 mutant, the best fit is provided by competitive 
inhibition.  This result confirms that the N-half nucleotide binding site is the allosteric site 
seen in the data of Ning, et al (19).   
Synergism between glucose 6-phosphate and ADP in inhibition—ADP and glucose 6-
phosphate were tested for synergism in inhibition of wild-type hexokinase I.  The hexokinase 
assay was modified to contain 1 mM ATP, 250 µM glucose 5 mM and MgCl2 for this 
experiment.    HKI was assayed without inhibitor as a comparison and results of the 
synergism experiment are shown in Table THREE.  The assay sample containing 40 µM 
AnGlu-6-P was inhibited 10.0±0.4% and the assay containing 2 mM ADP was inhibited 
22.7±0.3%.  The sample containing 40 µM AnGlu-6-P and 2 mM ADP in a single assay was  
inhibited by 32.1±0.1%. These results suggest that there is no synergistic inhibition between 
Glu-6-P and ADP in the case of HKI. 
Discussion 
In terms of solution kinetics, ADP inhibition of HKI was first shown to be 
noncompetitive relative to ATP in 1969, but the location of the allosteric site had never been 
identified (19).  Thirty years later the existence of a nucleotide bound in the N-half of HKI 
was discovered through crystallography (15,29).  The data presented in this manuscript 
definitively assigns a function to the N-terminal half nucleotide binding site.   
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Table TWO. 
ADP inhibition of wild-type and mutant HKI constructs. 
 
Enzyme 
Mechanism 
of 
Inhibition 
KmATP KiADP KiiADP 
  mM mM mM 
Wild-type, His-tagged Mixed 2.6±0.3 2.2±0.4 6±2 
α+2 Competitive 1.3±0.1 1.7±0.1 N.A. 
Thr232→Ala Mixed 2.3±0.3 2.3±0.6 6±2 
Asn384→Arg Competitive 1.7±0.2 1.7±0.2 N.A. 
 
 
 
 
Inorganic orthophosphate is capable of ameliorating Glu-6-P inhibition under normal 
physiological conditions (11).  At elevated levels; however, Pi acts as an inhibitor of HKI by 
biding to the active site of the enzyme (27).  The site responsible for the effect of phosphate 
on the kinetics of HKI has been shown to be the N-terminal half Glu-6-P binding site from 
crystallographic and solution kinetic studies (13,25).  The data shown in Figure TWO 
suggest that the Glu-6-P binding site and the ADP allosteric site are not equivalent.   
The first of the mutant HKI proteins in Figure TWO, α+2, separates the N- and  
C-terminal halves of the protein functionally and disallows communication across the 
interface.  Therefore, nucleotide binding to the N-half of HKI can have no effect on the 
active site.  This mutant showed that the allosteric site is not in the catalytic half of HKI. 
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Figure TWO.  ADP inhibition versus ATP of wild-type and mutant hexokinases.  Glucose 
concentrations are held constant at 1.6 mM.  The concentration of ATP is varied from 
0.5 to 2 mM.  ADP concentrations are are 0 mM (■), 1 mM (♦), 3 mM (▲), 6 mM (x) 
and 12 mM (+).  Plotted here is reciprocal velocity versus reciprocal ATP 
concentration.  Solid lines were generated from the parameters in Table TWO.  Panel 
A is wild-type HKI.  Panel B is the α+2 construct.  Panel C is the Thr232→Ala mutant 
and Panel D is the Asn384→Arg mutant.   
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Mutation of threonine 232 to alanine blocks binding of Glu-6-P/Pi to the N-terminal 
half site.  This mutation has no effect on ADP inhibition relative to ATP compared to the 
wild-type enzyme.  The result confirms the conclusion that the Glu-6-P/Pi binding site is not 
the location of ADP binding.   
The final mutation, Asn384→Arg, precludes binding of ADP to the nucleotide binding 
site in the N-half of HKI.  As shown in Figure TWO Panel D, the data clearly fit to a 
competitive inhibition model.  The Kii term in the noncompetitive inhibition model is 
irrelevant and the kinetic parameters are nearly identical to those of the α+2 mutant enzyme.  
This is the first example of apparent functionality of the nucleotide binding site in the N-
terminal half of HKI.   
Since there are two inhibitors binding to different locations on the protein, we tested 
wild-type hexokinase for synergism between inhibitors.  As the results in Table THREE 
show, there is no detectable synergism under these conditions.     
Rose and Warms proposed that a nucleotide binding site other than the active site was 
involved in removing HKI from the mitochondrial membrane in 1967 (11).  With the 
existence of recent crystal structures, it had been hypothesized that the N-half nucleotide 
binding site would be responsible for nucleotide induced release of HKI from the 
mitochondrial membrane (29).   
Because of the proximity of the site to the N-terminus, which is inserted into the lipid 
bilayer, the hypothesis seemed likely.  However, recent work showed that the nucleotide 
binding site involve in HKI release from the mitochondrion appears to be associating with 
the mitochondrion and not HKI (Chapter III).  The series of mutations that appear in this 
study were applied to mitochondrial release experiments in the presence of ATP and other  
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Table THREE. 
Synergism between ADP and glucose 6-phosphate in inhibition of HKI 
 
[Inhibitor] Percent Inhibition 
No Inhibitor 0 
40 µM AnGlu-6-P 10.0±0.4 
2 mM ADP 22.7±0.3 
40 µM AnGlu-6-P and 2 mM ADP 32.1±0.1 
 
 
 
nucleotides (Chapter III).  The analysis of the results suggest that mutations to any of the 
nucleotide binding sites produces essentially no change in the concentration of nucleotide 
required to remove half of the HKI protein from the mitochondria.   
It is not known how a nucleotide binding to the allosteric site of HKI can affect the 
active site.  Crystallographic studies with the Asn384→Arg should be able to provide further 
insight into the mechanism.  Comparison of structures of the Asn384→Arg to the wild-type 
protein should show some conformational differences that may provide additional 
information about how allosteric nucleotide binding affects the C-terminal half of HKI.   
References 
1. Wilson, J. E. (1980) Curr Top Cell Regul 16, 1-54 
2. Gonzalez, C., Ureta, T., Sanchez, R., and Niemeyer, H. (1964) Biochem Biophys Res 
Commun 16, 347-352 
3. Grossbard, L., and Schimke, R. T. (1966) J Biol Chem 241, 3546-3560 
 75 
   
 
4. Katzen, H. M. (1967) Adv Enzyme Regul 5, 335-356 
5. Lowry, O. H., and Passonneau, J. V. (1964) J Biol Chem 239, 31-42 
6. Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R. B., and Hay, N. 
(2001) Genes Dev 15, 1406-1418 
7. Bryson, J. M., Coy, P. E., Gottlob, K., Hay, N., and Robey, R. B. (2002) J Biol Chem 
277, 11392-11400 
8. Fiek, C., Benz, R., Roos, N., and Brdiczka, D. (1982) Biochim Biophys Acta 688, 
429-440 
9. Linden, M., Gellerfors, P., and Nelson, B. D. (1982) FEBS Lett 141, 189-192 
10. Azoulay-Zohar, H., Israelson, A., Abu-Hamad, S., and Shoshan-Barmatz, V. (2004) 
Biochem J 377, 347-355 
11. Rose, I. A., and Warms, J. V. (1967) J Biol Chem 242, 1635-1645 
12. Vyssokikh, M. Y., Zorova, L., Zorov, D., Heimlich, G., Jurgensmeier, J. J., and 
Brdiczka, D. (2002) Mol Biol Rep 29, 93-96 
13. Aleshin, A. E., Zeng, C., Bartunik, H. D., Fromm, H. J., and Honzatko, R. B. (1998) J 
Mol Biol 282, 345-357 
14. Aleshin, A. E., Zeng, C., Bourenkov, G. P., Bartunik, H. D., Fromm, H. J., and 
Honzatko, R. B. (1998) Structure 6, 39-50 
15. Aleshin, A. E., Kirby, C., Liu, X., Bourenkov, G. P., Bartunik, H. D., Fromm, H. J., 
and Honzatko, R. B. (2000) J Mol Biol 296, 1001-1015 
16. Aleshin, A. E., Fromm, H. J., and Honzatko, R. B. (1998) FEBS Lett 434, 42-46 
17. Tsai, H. J., and Wilson, J. E. (1995) Arch Biochem Biophys 316, 206-214 
18. Skaff, D. A., Kim, C. S., Tsai, H. J., Honzatko, R. B., and Fromm, H. J. (2005) J Biol 
Chem 280, 38403-38409 
19. Ning, J., Purich, D. L., and Fromm, H. J. (1969) J Biol Chem 244, 3840-3846 
20. Liu, X., Kim, C. S., Kurbanov, F. T., Honzatko, R. B., and Fromm, H. J. (1999) J 
Biol Chem 274, 31155-31159 
21. Bradford, M. M. (1976) Anal Biochem 72, 248-254 
22. Fromm, H. J., and Zewe, V. (1962) J Biol Chem 237, 1661-1667 
23. Leatherbarrow, R. J. (2001), 5 Ed., Erithacus Software Ltd, Horley, UK 
24. Kuzmic, P. (1996) Anal Biochem 237, 260-273 
25. Fang, T. Y., Alechina, O., Aleshin, A. E., Fromm, H. J., and Honzatko, R. B. (1998) J 
Biol Chem 273, 19548-19553 
26. Ferrari, R. A., Mandelstam, P., and Crane, R. K. (1959) Archives of Biochemistry and 
Biophysics 80, 372-377 
27. Ellison, W. R., Lueck, J. D., and Fromm, H. J. (1975) J Biol Chem 250, 1864-1871 
28. Ellison, W. R., Lueck, J. D., and Fromm, H. J. (1974) Biochem Biophys Res Commun 
57, 1214-1220 
29. Rosano, C., Sabini, E., Rizzi, M., Deriu, D., Murshudov, G., Bianchi, M., Serafini, 
G., Magnani, M., and Bolognesi, M. (1999) Structure 7, 1427-1437 
 
 
 
 
 76 
   
 
CHAPTER V.  GENERAL CONCLUSIONS 
The production of the histidine-tagged recombinant hexokinase I construct has 
allowed for many new experiments involving HKI association with the mitochondria that 
were not possible previously.  This protein has been shown to bind to the mitochondria in the 
presence of magnesium and be released with nucleotides and glucose 6-phosphate. These 
findings are similar to the properties of the native enzyme that have been previously 
published.  Presumably, conformational changes in the HKI protein due to glu-6-P binding 
cause the protein to be released from the membrane.  Alterations to putative glu-6-P binding 
sites precluding the molecule’s binding to mitochondria would affect the ability of HKI to be 
released. Chapter II proposes a model for glucose 6-phosphate-induced release from the 
mitochondrion.   Additionally, the N-terminal half glu-6-P/Pi binding site has been identified 
as the site responsible for release with this molecule.   
Chapter III proposes a model for ATP-induced release of HKI from the mitochondrial 
membrane.  We were able to conclude that the length of the nucleotide polyphosphate chain 
is an important factor in the ability of the nucleotide to induce release of HKI from the 
membrane.  Through mutational analysis, it has been determined that any mutation effecting 
a potential nucleotide binding site makes the protein less susceptible to nucleotide-induced 
release, but insignificant changes in the I0.5 values for the various mutants led us to conclude 
that ATP  binds to a site not associated with hexokinase, i.e., porin or another portion of the 
PTP complex.   
The results contained in Chapter IV demonstrate that the nucleotide allosteric site 
originally proposed for HKI have been confirmed from kinetic, nucleotide binding, and x-ray 
diffraction crystallographic studies. The series of mutations provided a clear relationship 
 77 
   
 
between the allosteric nucleotide binding site and ADP inhibition.  Precluding nucleotide 
binding to the N-terminal half nucleotide binding site eliminated the noncompetitive 
inhibition with data fitting to a competitive inhibition model nearly identical to that of the 
α+2 mutant.   
Future Research with Human Hexokinase 
The work presented in this dissertation has opened the door for many potential 
experiments with human hexokinases.  Experiments presented by Wilson with lipids (see 
Chapter I) could be further explored with the recombinant HKI.  We have hypothesized that 
the N-terminal nucleotide binding site may also bind phospholipids because of it’s proximity 
to the mitochondrial membrane.  Binding experiments through a series of mutations to 
residues that contact the phosphoryl- portion of the binding pocket may be able to shed more 
light on the orientation of the HKI protein on the mitochondrial membrane.  There appear to 
be some differences in the literature as to the association of HKI with the mitochondrial 
membrane.  Rose and Warms’ work suggested that HKI was interacting as a monomer on the 
surface of the mitochondrial membrane.  Later, Wilson showed data that HKI was, in fact, 
binding as a tetramer.  This question could be resolved with the recombinant HKI construct 
and extended to determine the number of hexokinase binding sites on the mitochondrial 
membrane; a question that is yet to be answered. 
Hexokinase II, or muscle hexokinase, has also been shown to bind to the PTP and can 
prevent apoptosis.  There are differences between the Type I and Type II proteins that could 
prove interesting.  For instance, the N-terminal half of HKI is inactive, but the HKII N-
terminal half is essentially equivalent to the C-terminal half, i.e., two active halves.  
Production of a recombinant form of this isozyme, and employing experiments similar to 
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those presented here should allow for a better understanding of how this protein functions as 
there is no crystal structure available.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
